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Abstract 
TUMOR IMMUNITY FOLLOWING ADENOVIRUS MEDIATED HERPES SIMPLEX 
THYMIDINE KINASE GENE TRANSFER TO EX PERIMENTAL RAT GLIOMAS 
By Mau l ik Raj Shah , Ph . D .  
A d i s sertat i on submitted in partial ful f i l lment o f  the 
requ i rements for the degree of Doctor of Phi losophy at 
V i rginia Commonwealth Univers ity . 
V i rginia Commonwealth Univers ity , 1 9 9 7 . 
Major Di rector: Dr . Jack L .  Haar , D i rector of Graduate 
Studi e s; Pro f e s sor of Anatomy . 
Co-Director: D r . Jay Ramsey , Adj unct Pro fessor o f  Anatomy; 
C l in i c a l  Assoc i ate - CGTB/NCHGR/NIH . 
Previous studi es have determined adenovirus mediated 
herpes s impl ex thymidine kinase gene trans f er (AV-TK) to be 
e f fect ive for the treatment o f  experimenta l g l i omas . In 
thi s  study we report three di stinct phenomenon . F i r st , 
animal s  with c omplete regres s i on o f  subcutaneous tumor s  upon 
intratumoral inj ections o f  AV-TK with c oncomitant 
Ganc i c lovir® (GCV) admini stration deve l oped tumor immunity . 
Thes e  anima l s  had the abi l ity to rej ect a subsequent 
inoculum of l ethal doses of tumor c e l l s . Thi s  tumor 
immun ity was l ong standing and protective as far as 6 months 
f rom the t ime o f  initial tumor ablation . Of interest , 
adopt ive tran s f er o f  splenocytes f rom AV-TK treated-tumor 
ablated animal s  to naive animals c on ferred res i stance to 
tumor f o rmat i on upon injection of lethal doses of tumor 
xi 
c e l l s . This data strongly indicated the mechan i sm o f  tumor 
immunity was c ell mediated . Further ana lys i s  o f  the ant i -
tumor immune response imp l icated CD8a8B cytotoxic T -
lymphocytes as the e f f ector c e ll . Anima l s  with c omplete 
tumor regre s s i on survived over 30 0 days and showed no s igns 
o f  tumor relapse . There fore , treatment o f  solid uni f oc al 
tumors with AV-TK and GCV may be abl e  to prevent tumor 
relapse through the generation of an ant i -tumor immune 
re sponse . 
Sec ondly , we determined that AV-TK and GCV treatment 
e f f i cacy was dependent on tumor ant igenic ity . Two d i f f erent 
subcutaneous tumor models were utilized; the weakly 
immunogen i c  9L and the strongly immunogenic RT2 . For the 
sam e  dos e  o f  intratumora l ly inj ected AV-TK , a greater 
percentage of RT2 tumor were e l iminated as c ompared to 9 L . 
F inal survival e f f i cacy was dependant on the tumor type and 
the init i a l  tumor s ize . 
In studying the importance o f  host immunity in tumor 
progre s s i on ,  we have determined that in vivo, the GCV 
med i ated bystander e f f ect was not su f f i c i ent to result in 
X l l  
tumor eradication without invo lvement o f  a host immune 
response . In athyrnic rats , 9L tumors failed to regress upon 
AV-TK and GCV treatment . In contrast , tumors of similar 
size were abl ated upon treatment in immunocompetent anima l s . 
Of related significance , adenovirus mediated gene 
transfer facilitated generation of tumor immunity . Animal s  
with tumors ablated by AV-TK and GCV treatment deve l oped an 
anti -tumor immune response which was protective against 
further tumor engraftment . In contrast, a lternative 
treatments such as surgical excision of subcutaneous g liomas 
or tumor vaccination was not sufficient to protect against 
secondary tumor cha l l enge . Inj ection of adenovirus a ltered 
the amount and phenotype s  of tumor infi ltrating lymphocytes 
from the NK phenotype towards tumor specific CDS+ CTL c e l l s . 
This immunomodulatory property was potential ly responsible 
for generation of the immune response . 
Therefore, AV-TK was effective through two mechanisms . 
Transfer of the H SVTK gene c onfered GCV sensitivity 
resulting in substantial tumor regres sion and the adenovirus 
backbone s erved as an immune adj uvant to augment generation 
of host tumor immunity . This immunomodulatory property of 
adenovirus vectors is an added advantage to their use for 
c ancer gene therapy . 
A Rationale For This Study 
The majority of mal ignant central nervous system (CNS) 
tumor s  are refractory to current modes of treatment 
inc luding surgery , radiat i on , chemotherapy and bio logical 
response modifiers. The average survival of pat i ents with 
g l i oblastoma multiforme , the most mal ignant form of g l i oma , 
post- operat ively i s  approximately 12- 13 months. The high 
morbidity and mortal ity a s s ociated with these CNS tumors has 
resu lted in the deve lopment of alternative treatment 
moda l it i e s  such as gene therapy . 
Gene therapy offers potent i a l  as a treatment strategy 
for primary mal i gnant CNS tumors . C l inical human t r i a l s  
uti l i z ing herpes s impl ex vi rus thymidine kinase gene 
(HSVTK)transfer by a retrovirus vector into brain tumor s  
have shown s ome efficacy. However ,  retrovirus medi ated 
suicide gene transfer to focal neoplasms has multiple 
d i sadvantages inc luding poor transducti on efficiency , 
diff iculty in v i rus concentration and in vivo v i ru s  
inactivati on. To overcome these l imitations , we have 
created an a lternate viral vector system , a recombinant 
adenovirus expres s ing the herpes s impl ex thymidine kinase 
1 
gene (AV- TK)  . This vector infected ma l i gnant gl ioma ce l l s 
with much h i gher e f f i c i ency than reported for retrovirus 
2 
med i a t ed gene t rans fer . I n  a rat mode l ,  AV-TK treatment has 
resul ted in regre s s i on and cure of subcutaneous and 
intracran i a l  t ransp l anted g l i omas . However ,  factors 
gove rning trea tment e f fi cacy have yet to  be de termined . 
S tudi es in our l aboratory indi cated that anima l s  treated 
with AV-TK ma y deve l op ant i - tumor immuni t y . Interes t in g l y ,  
tumo r eradi cat ion ma y be augmented and pos s ib l y  dependent o n  
t h e  gene r a t i on o f  this ant i - tumo r immune re sponse . 
Charact e r i z ing the immune mechani sm governing ant i­
tumor immuni t y  and determining the requ i rements for i t s  
generation wi l l  give ins i ght into the poten t i a l  f o r  AV-TK as  
a t reatment f o r  un i focal systemic and CNS tumors . 
Specific Aims 
The main obj ec tive o f  this s tudy is to charac t erize the 
anti - tumor immune response generated by the trea tment o f  
malignant g liomas wi th herpes simp lex virus thymidine kinase 
gene trans f e r  using an adenovirus vec tor and to evaluate the 
factors responsible for its  generation as wel l as the 
immunomodu l a t ory ac tivi ty of AV-TK in mediating tumor 
eradication . 
Our fir s t  goal is to characterize the immune mechanism 
responsib l e  f o r  l ong term tumor immuni ty in animal s  treated 
with AV-TK and GCV . The immune mechanisms inves tigated wi l l  
inc lude antibody and c ompl ement media ted cyto lysis, antibody 
dependent c e l l  mediated cytotoxicity , CDS+ MHC c l as s  I 
res t ric ted cyto toxicity and NK c e l l  cytotoxicity . 
mechanism o f  tumor immunity is determined the 
immunophenotype of the e f fector mechanism wi l l  be 
Onc e  the 
charac terized . Further characterization o f  the immune 
response wi l l  a l s o  require determining the abi lity of the 
immune e f fec tor mechanism to mediate tumor regres sion �n 
vivo . 
3 
4 
Al s o  o f  int e r e s t  are the factors governing adenovirus 
mediated generation of tumor immunit y .  The ro l e  o f  tumor 
antigenicit y ,  host  immunocompetence and the puta t ive HSVTK 
bystander e f fect wil l  be evaluated in addition to adenovirus 
mediat e d  e f fe c t s  such as  local in f l ammation . 
Las t l y ,  the advantage o f  AV- TK treatment over 
t raditiona l  methods for the treatment of foc a l  tumors wi l l  
b e  s tudied . This comparison wil l include gene therapy, 
tumor vaccination and surgica l  tumo r  remova l .  Eva luation 
wil l  inc l ude tumor free survival and protection f rom further 
tumor cha l l enge s . 
Literature Review 
Pr imary tumors of the c entral nervous system (CNS) are 
the second mo st c ommon neoplasms of chi ldren and in adults 
are more preval ent than systemic Hodgkin's di sease1 . Each 
year in the United States approximately 14 , 0 0 0  cases o f  
pr imary CNS tumors are diagnosed2 . To date , no curative 
treatment f o r  most types o f  neuroectodermal CNS tumors 
exists . Current treatment cons i sts o f  surgical remova l o f  
the neopl asm f o l l owed by radiation with or without 
chemotherapy2 . However, there i s  s igni f icant morbidity 
a s s o c i ated with thi s  treatment regimen and in very few cases 
c an it be c on s idered a succe s s . For mal ignant gl i omas , 
there i s  a poor l ong term progno s i s  with a mean surviva l  
t ime f o l l owing treatment o f  approximately 12- 1 8  months 3 . 
The most c ommon CNS tumors are neoplasms o f  
neuroectodermal orig in whi ch inc lude the c l a s s i f i c at i ons o f  
a strocytoma , o l igodendrogl i oma , g l i oblastoma mult i forme , 
ependymoma and medu l l oblastoma . O f  the s e  tumors ,  
g l i obl astoma multi forme i s  the most mal ignant primary brain 
tumor c omprom i s ing 5 0% of CNS tumors of chi ldren and 25% o f  
intracranial tumors i n  adu lts4 . Gl ioblastoma mult i forme 
5 
6 
represents the c l a s sic brain tumor in t e rms o f  patho logy and 
tumor progres sion . G l iobl a s tomas t end to be focal l e sions 
which do not me t a s t a size outside o f  the CNS5 • I ns tead,  
these tumors s lowl y  infil trate the brain parenchyma l eading 
to progres s ive CNS s ymptoms . Unlike s ys t emic tumo r s ,  a much 
sma l l er tumo r  burden is necessary to be lethal 2 • I t  is 
e s timat e d  that a 1 0 0  gram CNS tumor is invariabl y  f a t a l . I n  
t h e  c a s e  o f  g l iobl a s toma mul tiforme treatment mus t  be 
considered p a l l iative for it is rarely curative . 
Due to  the ine f fectiveness o f  current treatment 
moda l itie s , many res earchers attempting to improve patient 
surviva l  r a t e s  have concent rated on a l t e rnative bio logica l  
approaches s uch as  gene therapy and immuno therapy rather 
than pharmaco l ogical methods of t reatment . 
Tumor Biology 
The body o f  s c i ent i f ic literature encompass ing the 
f i eld o f  tumor b i o l ogy is qu ite vast6 (see review by 
Sherbet , 19 87) . Carcinogene s i s  1 s  a multi step proc e s s  
involving genet i c  alterations within a c e ll7 . The 
accumulati on o f  geneti c  de fects o ften leads to uncontrolled 
prol i ferat i on8 . Advance s  in our understanding o f  the 
geneti c  bas i s  o f  c ancer allows for gene modi f i cat i on to be a 
viable strategy for cancer treatment . A var i ety o f  
proto c o l s  exi st f o r  the management o f  cancer . However , mo st 
treatment regimens inc lude surgery , radiation and 
chemotherapy or a combination to be e f fective . The lack o f  
tumor spec i f i c ity o ften limits the use fulness o f  the se 
strategies resulting in s ign i f i cant s ide e f f ects and 
morbidityl . Thus , res earchers have explored alternative 
manipulat ions . O f  thes e  experimental protoc o l s , methods to 
augment host immunity s eem to be one o f  the most promi s ing9· 
10, 11 The r o l e  o f  immune responses in modi fy ing tumor 
progres s i on i s  well 12 . 
Immunode f i c i ent or immunocompromised pat i ents lacking 
the abi l ity to mount a c ellular immune response are 
7 
8 
susceptible to  tumo rs sugge s t ing that immune e f fector c e l l s  
funct i on i n  t h e  surve i l l ance against neop l a sms 1 3 • When the 
concept of immunosurvei l l ance was f i r s t  po s tulated1 2 , the 
exact immune mechani sms re sponsible for recogn i t ion of the 
tumor ant i gens was un known . Many research groups have s ince 
shown that h o s t  r espons e s  against tumors are predomina t e l y  
by c e l l u l a r  mechani sms 1 4 ( S ee Revi ew by Baxevani s ,  1 9 9 4 ) . 
Three immune c e l l  c l a s s e s  have been des cr ibed w i th ant i ­
tumor a c t i vi t y . The se c l a s s e s  are cytotox i c - T  l ympho cytes 
( CTL)  charac t e r i zed by ant i gen speci f i c i t y1 5 , Natural Ki l l e r  
Ce l l s  (NK) whi ch l a c k  MHC r e s t r i c t i on1 6  and L ympho kine 
Act ivated K i l l e r  ce l l s  (LAK) de rived by high do s e  cytok ine 
s t imul a t i on ex vi vo17• Al though a l l  o f  these di f ferent 
immune ce l l  popu l a t ions ( CT L ,  NK , and LAK) have shown 
reactivi t y  against  tumo r s ,  the mo s t  predominant 
phys i o l o g i c a l  mechani sm i nvolves CTL1 4 • Gene r a t i on o f  CTL 
re sponses can be divided into two pha s e s . The f i r s t  pha s e  
i nvo lves interact i on o f  regu l atory l ympho cyt e s  ( usua l l y  
expre s s ing CD4 antigen ; CD4 + )  with tumo r ce l l s  o ften by the 
recogn i t i on of tumo r a s s o c i ated anti gens ( TAA ) 1 8 • The 
s econd phase i nvolves regulatory l ymphocyte activation o f  
c yto l yt i c  T - l ymphocyt e s1 9 • 
Glioma Immunobiology 
In previous year s , the central nervous system was 
c ons i dered an immune privi l eged s ite due to a l ac k  o f  
lymphati c  drainage and the protective nature o f  the blood­
brain barrier (BBB)20 . In 1 9 7 7  however, Albr ight et al . 21 
reported rej ection of tumor al logra fts in the CNS . Other 
s imi l ar studies have resu lted in a greater under standing o f  
acqu i red immune responses t o  tumors o f  the CNS22• 23 
The role of the immune system in g l i oma progres s ion 
stems f rom the observation that patient survival c an be 
c orrel ated to the degree o f  tumor inf i ltrat i on by 
lymphocytes24 . Another important observation was that 
peripheral bl ood lymphocytes have the abi l ity to cross the 
BBB and migrate into an intracranial tumor25 . In many 
cases, g l i a l  tumor c e l l s  have been shown to expre s s  anti gens 
which c an be l o c a l ized by ant ibody staining2 6• Thes e  
studies que st i on the axi om of the brain a s  an immune­
privi leged organ . C l early there i s  a s e l ective interact i on 
o f  the host immune system with CNS t i s sue . 
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Glioma Associated Antigens 
Recen t l y  there has been a great interest i n  g l i oma 
spe c i f i c  ant i gens that has  been fue l ed by the deve lopment o f  
a variety o f  mono clonal antibodi es react ive against g l i a l  
tumors26 • The s e  anti gens have not proven to be u s e fu l  in 
therapeut i c  regimens , howeve r ,  due to the i r  l ac k  o f  tumor 
spec i f i c i t y27 • Ant ibody s t a ining has loca l i z ed many o f  
these ant i gens to  no rma l a s  we l l  as ma l i gnant brain 
t i s sue28 • 
The maj o r i t y  o f  these g l i oma associ ated mar kers 
i den t i fy int race l lu l a r  intermedi ate f i l ament pro t e ins 26 • 
This c l a s s  o f  proteins i s  as sociated wi th c e l l u l a r  
di f feren t i a t ion and i s  expressed through deve l opment29 • 
Tumo r i gene s i s  usua l l y  invo lves c e l l u l a r  revers ion to  a l e s s  
d i f f erent i at ed s t ate in whi ch these f i l ament pro t e ins a r e  
p roduced29 • The f i r s t  o f  these tumor-as sociated anti gen 
prote ins d i s covered was g l i a l  fibri l l ary acidic protein 
( G FAP ) , an indi cator o f  a s t rocyte l ineage30 • Other g l i oma 
a s s o c iated ant i gens in t h i s  fami l y  include the neuro f i l ament 
proteins n e s t i n  and viment in31 • Nes t i n  expre s s ion is a l s o  
detected i n  neurons a t  t h e  ear l i e s t  s t age o f  the i r  
d i f ferent i at i on but d i s appears by the s ixth we e k  o f  
deve lopmene2 • 
The next l argest group o f  g l i oma associ ated anti gens 
are c e l l  surface anti gens . Many ma l i gnant g l i omas 
overexpress growth factor recepto rs including p l a t e l e t  
der i ved growth f a c t o r  receptor ( PDGF } 33  and epidermal 
der i ved growth factor receptor ( EGFR } 34 • The role of the se 
ant i gens i n  g l i oma p rogre s s ion i s  di scussed in a revi ew by 
Kurpad e t  a l . 26 • In  summa r y ,  express ion o f  the se g rowth 
factor receptors makes cel l s  susceptible to uncont rol led 
growth upon s t imu l a t i on with the receptor l i gand whi ch i s  
s ecreted a s  a no rma l phys iologic paracrine factor . 
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I n  animal mode l s ,  gl i oma s have been shown to  express 
ant i gens against whi ch ce l l ul a r  immune responses can be 
generated35• 3 6 • Cel lular immune re spons es against brain 
tumo r s  in these mode l s  have been ant i gen speci f i c . However ,  
c l in i ca l l y  onl y a s ingle t r i a l  ut i l i z ing human g l i oma ce l l  
immun i z a t i on was mode r a t e l y  succe s s ful37 • The l ack o f  a 
natural l y  o ccurring cel l u l a r  immune response during g l i oma 
progre s s ion has been a t t r ibuted to poor anti gen presentat i on 
a s  a cons e quence o f  g l i oma induced immunocomprom i s e38 • 
Glioma Induced Immunocompromise 
Peripher a l  blood l ymphocytes from patients wi th g l i oma 
have a de creased capa c i t y  to pro l i ferate in response to the 
mi togens Phytohemagglutinin ( PHA} 39 or  Concava l in A ( Con A}  4 0 
and a l s o  s how reduced I L - 2  product i on upon s t imul a t ion4 1 • 
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Furthermor e ,  there i s  con s i de rabl e  evidence tha t  Tumor 
Growth Factor-Beta ( TGF-B) i s  secreted by ma l i gnant g l i a l  
tumors4 2 • Thi s g l ycoprot e i n  inhib i t s  proli fera t i on and 
cytotox i c  activity o f  LAK cel l s4 3• Much evidence exi s t s  
po inting to  TGF-B as  the pr imary immuno suppressive a gent 
assoc i a t ed wi th g l i omas4 2 • Other potent i a l  irnrnunomodulators 
resul t ing i n  decrea s ed ant i - tumor T-cell act ivi t y  are 
Interleukin 1 4 4 , Tumo r-Necro s i s  Factor-alpha4 5 , and 
Interferon- gamma4 6 • I n  other cases , the gene ral l a c k  o f  
pro f e s s ional anti gen presenting c e l l s  wi thin the CNS has 
been a s s o c i ated with the deve lopment o f T-ce l l  anergy4 7 • 
Glioma Specific Immunity 
G l i omas have been shown to be hi ghly ant igenic i n  
animal mode l s  but we a k l y  immunogen i c  un less  e f fector c e l l s  
a r e  s econda r i l y  st imu l a t ed w i th I L - 2 4 8• The favo red 
exp l an a t i on is that tumor bearing anima l s  may pr ime 
l ymphocytes into cyto l yt i c  precursors but wi thout cytotoxic 
activity a s  a resu l t  o f  s ys t emic immuno suppre s s i on . 
Ce l l  mediated g l i oma immune re sponses are rare4 9 • 
Unl i ke o ther tumors , g l i omas are unique in that very f ew 
reactive T I L  can be i s o l ated from tumors 50 • There i s  a l s o  a 
decrease i n  the amount o f  MHC C l a s s  I expre s s ion on t he 
tumor ce l l  sur face51 ' 52 T - c e l ls i s o l ated f rom g l i omas o ft en 
have a de f e ctive I L- 2  receptor and l a c k  the ability to  
proliferate in response t o  appropriate s timuli4 1 • 
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Given the antigenicity o f  gliomas and the poor 
prognosis with t raditional methods of treatment a numb e r  o f  
r e s e archers have a t t empt ed cel lular immunotherapy as  a means 
o f  a l te ring tumo r progression . 
Glioma Immunotherapy 
Cel l u l a r  immunotherapy, which invo lves ex vi vo 
activation and expansion o f  l ympho cytes before sub s e quent 
r eint roduc tion into the host , has the pot ential to 
circumvent the glioma induced immune s ys t em suppres s ion and 
to  potentiate the ho s t  anti- tumo r immune respons e . E a r l y  
s tudies o f  adoptive c e l l u l a r  immunotherapy invo lved t h e  u s e  
o f  l ympho kine activated kil ler (LAK) c e l l s 53 • LAK ce l l s ,  
derived f rom l arge granu l a r  l ymphocytes found within the 
peripheral b l ood,  were shown to have non- specific cytol ytic 
act ivity a gain s t  autol ogous and a l l o geneic tumor c e l l s  i n  
vi t ro54• C yt o l ytic activit y is dependent on stimu l a t ion 
with I L - 2 1 6 • Through a mechanism which is s til l unc l e a r ,  
these ce l l s  exhibited s e l e ctive l ysis o f  tumo r cel l s  and 
remained r e l a tive l y  non- toxic to normal tis sue ce l l s 55 • In 
vi vo adoptive immuno therapy s tudies with LAK ce l l s  and I L - 2  
showed success in a varie t y  o f  anima l tumor mode l s  l eading 
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to c l inic a l  t ria l s 56• Howeve r ,  it was noted that LAK cel l s  
showed poor migration into the CNS57• There fore direct LAK 
ce l l  in fusion into the tumo r cavit y fo l lowing resection was 
a t t empt e d58' 59' 60 The s e  therapeutic protoco l s  resu l t ed in 
mul tipl e  s evere side e f fects and mixed clinical outcomes . 
Ove ra l l, thes e  c l inic a l  t ria l s  f ailed to  show a consist ent 
increase in patient survival over st andard treatment 
methods . I n  addition,  the s ys t emic side e f fects a s s ociated 
with LAK and I L- 2  adminis tration limit ed the feasibility of 
LAK immuno therapy61 • The factors in f l uencing clinica l  
outcome are a l s o  unc l e a r . Al though tumo rs o f  a similar 
patho l o gica l  grade and location were t reated,  one cannot 
dis tinguish the e f fectivene s s  of surgical res ection f rom LAK 
t re a tment . 
C e l l u l a r  immunothe rapy has recent l y  cent ered on the use 
of  antigen spe cific cytotoxic c e l l s . Early studie s with 
patients with me l anoma found that l ymphocyt e s  harves ted f rom 
within tumo r l esions had the ability to l yse auto l o gous 
tumo r when expanded ex vi vo and r eintroduced into the tumor 
bearing host 62 • The antigen specificit y o f  the s e  tumor 
in fil t r ating l ymphocyt e s  ( T I Ls )  l ed to  similar a t t empt s  for 
g l iomas 53 • G l ioma in fil trating l ympho cyt e s ,  howeve r ,  were 
predominat e l y  of the T - suppressor pheno type as  a cons equence 
of g l ioma e l aborated immuno suppre s sive factors 63 • There was 
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a l s o  con f l i ct ing data o n  the ab i l i t y  o f  g l i oma der ived T I L  
t o  l ys e  aut o l o gous tumor64 • I n  a study o f  adopt i ve l y  
t ransferred I L - 2  expanded T I L  c e l l s  in mi c e ,  hepat i c  
meta s t a s e s  showed regr e s s ion but l i t t l e  e f fect w a s  shown on 
p r imary brain tumo rs 65 • I nterestingly howeve r ,  recent 
studies have shown e f fect ive adopt ive immunothe rapy 
t r ea tment o f  g l i oma bearing rats us ing spleen e f fector ce l l s  
from anima l s  immuni z ed wi th a known antigen i c  g l i oma66 • T­
l ymphocyt e s  f rom immuni z ed anima l s  were s t imu l ated i n  vi t ro 
w i th auto l o gous tumo r and I L - 2 . Immuno therapy w i th the se 
e f fector c e l l s  resulted in anima l s  rej ecting autol ogous 
intracrani a l  tumo r s . Thus , adopt ive c e l l u l a r  immuno therapy 
may requ i r e  the use of anti gen speci f i c  sens i t i zed 
l ymphocyt e s  to medi ate cytotoxi c i t y . 
Although a maj o r i t y  o f  g l i oma i n f i l trat ing l ympho cytes 
are of the tumor suppres sor phenot ype and have mixed 
cyto l y t i c  abi l i t y  aga i n s t  auto l o gous tumor , up to  1 4 %  o f  
c e l l s  were CD5 6 +  and 4 %  were CD1 6+ 67 whi ch are known ce l l  
surface mar kers o n  NK cel l s . Recen t l y ,  NK cel l s  negat ive l y  
s e lected b y  f l ow c ytome t r y  were shown to  have part i a l  
c ytotox i c  a c t iv i t y  against e s t ab l i shed g l i oma ce l l  l ines and 
fresh surgi c a l  specimens wi thout prior I L - 2  s t imul a t ion68 • 
A potent i a l bene f i t  to  immuno therapy with NK ce l l s  i s  the 
l a c k  o f  s ys t emic s i de e f fects a s s o c i ated w i th I L - 2  
admini s tr a t i on . P a t i ent t r i a l s  w i th NK ce l l  immuno the rapy 
are pending . 
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Another t ype o f  immunotherapy protocol i s  de signated 
a c t ive nonspeci f i c  immunothe rapy o r  immuni z a t i on . Thi s 
t reatment method invo lves the use o f  a gents to augment the 
host immune re sponse . Agents whi ch enhance immune re sponse 
gene rat ion or adj uvants are inj ected w i thin the tumo r as  a 
means o f  induc ing an i n f l amma tory re sponse or  as  a me ans o f  
up- r e gu l a t ing a tumo r spe c i f i c  respons e .  Cl i n i c a l  t r i a l s  
have been conduc ted ut i l i z ing baci l l e  Calmette-Guerin 
( BCG ) 69 , puri f i ed pro t e i n  extracts of S t reptococcus p yogenes 
( OK- 4 3 2 ) 70 , Corynebacterium Parvum71 , l evami s o l e72 and v i ruses 
such a s  mumps73 and rab i e s74 as  a me thod to s t imul a t e  the 
host immune re sponse . These t r i a l s  have not been succe s s ful 
in al t e r ing p a t i ent survival 53 mo s t  l i ke l y  a consequence o f  
host immuno suppre s s i on a l though increased l ymphocyte and 
monocyte i n f i l trates into tumo r were reported75 • 
Cancer Gene Therapy 
I dent i f i cati on o f  numerous oncogenes and tumor 
suppres sor genes and greater understanding of the i r  
mo lecular and c e l lu lar interact i ons h a s  fundament a l ly 
changed our perc ept i on o f  c ancer . With thi s  increased 
knowledge into the genet ic bas i s  o f  c ancer it has bec ome 
pos s ib l e  to a lter tumor growth k inet i c s  by gene 
modi f i c at i on10· 7 6  D irect gene therapy for cancer i s  based 
on the premise that modi f i c ation of c ancer cel l s  in a 
pat ient by the tran s f er o f  an exogenous gene could result in 
multip l e  new treatment options . Tumor growth 
c haracter i st i c s  could be altered by the trans fer o f  tumor 
suppres s or gene s77  or ant i - sense oncogene constructs78 . 
Another opt i on i s  to trans fer genes resulting in tumor c e l l  
death such as toxin genes o r  genes induc ing apopto s i s 79 . 
Unf ortunately , no gene trans fer mechani sm exists that a l l ows 
for spec i f ic target ing of d i s s eminated cancer or that c an 
guarantee gene trans fer to a l l  c e l l s  in a local ized tumor . 
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Suicide Genes 
Due t o  the l imitation of gene t rans fer to d i s s eminated 
cancer ce l l s ,  suicide gene therapy has focused on the 
trea tment o f  l o ca l i zed focal depo s i t s  o f  cancer80 • S u i c i de 
genes were f i r s t  deve loped as  a s a fe t y  precaut ion for 
r e t rovirus vector based gene t rans fer used in the t re atment 
o f  met abo l i c  di so rde rs81 • Retrovi ruses integrate randoml y 
within the host ce l l  genome l eading to the po s s ibi l i t y o f  
i n s e r t i onal mutagen e s i s  a s  a consequence o f  provi rus 
integra t i on wi thin a tumo r suppressor gene or 
protooncogene82 • I f  a suicide gene was inc luded w i thin the 
retrovi rus vec t o r ,  then a ma l i gnancy result ing from 
r e t rovirus gene t rans fer could be contro l l ed . 
The two sui cide genes extens ive l y  rese arched are the 
herpes s imp l ex thymi dine kinase gene83' 84 and the cyt o s i ne 
deaminase gene85 • Bo th genes invo lve the c e l l u l a r  
nucl e o t i de u t i l i zat ion p athways85' 86 • The mo st pr edominant 
s u i c i de gene used is the herpes s imp lex thymidine kina s e  
gene ( HSVTK ) 87 • Herpe t i c  infect ions a r e  contro l l e d  by the 
antivi r a l  agent Ganci c l ovir® ( GCV) 88 • The herpes s impl ex 
v i rus thymidine kinase gene product phosphorylates GCV to  
produce GCV-tr ipho sphat e  whi ch acts as  a DNA cha in 
t erminator and inhib i t s  DNA po l yme rase activi t y89 • E a r l y  
exper iment s  by Moo l t en e t  a l . showed that t rans fer o f  the 
HSVTK gene to  cancer cel l s  rendered them sensitive to GCV 
cytotoxicit y i n  vi t ro90• Further studies have shown that 
t r an s p l anted tumo r ce l l s  engineered to  express the HSVTK 
gene coul d  be eliminated by GCV adminis t ration91 • 
Bystander Effect 
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The l arge s t  l imita tion for direct gene therapy remained 
the need to modify a l l  cancer ce l l s  within a localiz ed 
deposit o f  cancer . Intere stingl y ,  it was noted in vi t ro 
that when mixtures o f  HSVTK cont aining tumor cel l s  and non­
HSVTK containing c e l l s  were mixed togethe r ,  there was no 
diminished cytotoxicit y by GCV92• Certain tumors showed 
comp l e t e  regres sion in vi vo when only 50% of ce l l s  were 
modified by HSVTK gene t rans fer93 • This phenomenon o f  
amplified GCV toxicit y to  non-modified c e l l s  has been termed 
the bys t ander e f fect . The bys tander e f fect appears to be 
mediated by the t rans fer of the tox i c  nuc l eotide ana l o gue 
GCV-phosphat e  via gap j unc tions 94 • The evidence for gap 
j unc tion media t ed trans fer o f  toxic me t abolites s t ems from 
an e a r l y  observation that the bys t ander e f fect is dependent 
on ce l l  density95 • Invariabl y ,  ce l l s  growing in suspension 
show poor or  nonexis tent byst ande r e f fect while c e l l s  with 
good bys t ander e f fect require c e l l  to ce l l  contact . To 
confirm the requirement for c e l l  cont a c t ,  R .  Touraine has 
conducted e l e gant exper iments us ing transwe l l  p l at e s  where 
non- t ransduced and HSVTK transduced c e l l s  are phys i c a l l y  
separated b u t  share extracel lular media . I n  the s e  
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experiments no tox i c i t y  to non- transduced c e l l s  was detected 
sugg e s t i ng that conferred toxi c i t y  i s  not mediated by a 
s ecreted s ub s t ance from HSVTK po s i t ive ce l l s 96 • Regardl e s s  
o f  t h e  mechani sm,  the bys tander e f fect a l l ows GCV to  exert 
toxi c i t y  to  untransduced c e l l s . 
The ex i s t ence o f  the bys tande r e f fect ma kes di rect gene 
transfer of the sui cide gene HSVTK a feasible tre a tment 
op t ion s i nce o n l y  a fraction of the tumo r mass needs to be 
mod i f i ed for GCV to exert i t s  ant ineop l a s t i c  e f fect92 • 
Based on these e a r l y  exper iment s ,  di rect gene therapy for 
cancer was a t t empted97• The l argest prob l em was the l ack o f  
an e f fect ive i n  s i t u  gene de l ivery method . 
Retrovirus Gene Therapy 
The f i r s t  viral  gene therapy vectors with demonstrated 
abi l i t y  to  trans fer exo genous genes were retrovi ruses based 
on the Mo loney Murine Leukemi a Virus 98• To make these 
vectors , a c e l l  l ine ( PA3 1 7 ) was created cont aining a l l  
genes except f o r  the c i s  el ements required for pac kaging the 
viral genome99• This packaging ce l l  l ine produced empty 
r e t rovirus v i r i ons unt i l  t rans fected with nuc l e i c  acid 
containing the viral pac kaging signal and f l anked by the 
viral long t e rminal repea t s100 • 
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Unfortuna t e l y  there are many dis advantages a s s oc i ated 
with in si t u  retrovirus gene tran s fe r . Ret rovirus vectors 
can be p roduced only a t  low titers of approximate l y  1 05-1 06 
infectious virions per ml101 • Furthermore , the t r ans gene 
expressing ret rovirus canno t be concentrated from the 
pac kaging c e l l  supernatant 102 • Ret rovirus transduction is a 
receptor media ted process and there fore is dependent on the 
sur face expression of the retrovirus re ceptor101 • The 
maj ority of tumo r ce l l s  have poor transduction e f ficiencies 
with r e t rovirus cont aining supernatant without additional 
manipulations 1 02 • Therefore , ret rovirus cont aining 
supernatant for gene t rans fer to tumo r ce l l s  i n  vi vo is 
impractic a l . Additiona l l y ,  retroviruses are inactivated at 
3 7°C by human serum80 • With the s e  limit ations , e f fective 
tumor t ransduction would require mu l tip le infusions o f  
vector which is not feasib l e . 
To ove rcome these limitations ,  vector producing c e l l s  
were utilized i n  si t u93• Vector producing ce l l s  are cel l s  
which continuous l y  produce and s ecrete ret rovirus partic l e s . 
A murine fibrob l a s t  retrovirus producer ce l l  line PA3 1 7  was 
created to  de l iver HSVTK gene cont aining retrovirus e s 100 • 
This vec t o r  producer c e l l  line has shown some succe s s  in 
2 2  
modifying the progres s ion o f  tumors in rats93• 97 • Based on 
these e a r l y  dat a ,  clinical t r i a l s  of p a t i ents wi th 
g l iobl a s t oma mul t i fo rme were a t t empted103 • To overcome many 
o f  the l imi t ations a s s ociated with ret rovirus based gene 
t r ans f e r ,  a l t e rnative viral ve ctors were s ought . 
Adenovirus Vectors 
Adenoviruses were dis covered by Rowe et a l . in 1953104 
during a t t empting to cul t ivate epithelial ce l l s  f rom pat ient 
adeno i ds . The se virus e s  were quic kly ident i f ied as  one o f  
the p rime etio l o gica l  agents re spons ib l e  for acute vir a l  
re spir a t o ry dis e a s e  as we l l  as o cu l a r ,  gastroint e s t i na l ,  and 
urinary d i s e a s e s 105 • S i nce their original discovery a t  l e a s t  
4 1  s t rains in fect ing humans have been discovered whi ch a r e  
further s ubdi vided i n t o  a var i e t y  o f  c l a s s e s  by the i r  
antigenic de t e rminants106 • 
The e a r l y  impetus for s tudying adenovi ruses arose f rom 
c l inica l needs . Howeve r ,  the ease with whi ch these viruses 
could be propagated in cul ture l ed to mul tiple s tudie s into 
vira l  s t ructure 105 , func t ion 105 , replication1 07 and 
t rans f o rma t ion1 08 • B e s i des increas ing our unde r s t anding o f  
vira l  pathogene s i s ,  a great amount o f  in formation was 
gener a t ed on the regu l a t ion and funct ion of adenovirus genes 
as  mode l s  for eukaryo t i c  t rans cript ion,  RNA pro c e s s ing and 
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t rans l a t i on ( S ee revi ew by Kremer and Perri caude t ) 109 • I n  
fact , mo re i n forma t i on h a s  been gathered o n  adenovi rus than 
any o ther v i rus wi th the excep t i on o f  the Human 
Immunode f i c i ency Virus in recent ye ars . 
Adenoviruses are non- enve loped i co sahedral doub l e  
s t r anded l inear DNA viruses w i t h  a genome o f  36 k i lobases . 
The genome i s  divided into early genes and late genes on the 
b a s i s  of their a c t iva t ion during viral rep l i ca t i on1 07 • E a r l y  
genes encode p r o t e i n s  invo lved in rep l i cat ion o f  t h e  v i r a l  
genome whi l e  t h e  l a te genes encode t h e  viral s t ructural 
prote ins . 
Mo s t  rep l i c a t i on de f i c i ent adenovi rus ve ctors are made 
f rom adenovi rus s erotype 5 and are non-oncogeni c  in 
humans1 10 • These vectors are made rep l i cat ion de f i c i ent by 
d e l e t ion of the E l a  and E l b genes 1 11 • These genes encode 
t r anscript i on factors nece s s ary for the activa t i on of early 
region promoters 1 07 • Wi thout E l  funct ion,  pro t e ins required 
f o r  viral genome repl i ca t i on are not t ranscribed a t  l eve l s  
s u f f i c i ent t o  ma intain the lytic viral l i fe cyc l e1 1 2 • I n  
o rder to grow E l  de l eted re comb i nant adenovi rus e s , a human 
k i dney ce l l  l ine , 293, wh i ch has a sheared piece o f  
adenovirus integrated into i t s  genome i s  ut i l i z ed1 1 3 • This 
integrated gene t i c  fragment produces El proteins whi ch can 
t rans compl ement El funct i on1 1 3 • Recomb inant adenov i rus 
vectors are made by int roducing a t rans gene cassette into 
the de l eted El region o f  adenovi rus . 
The advantages o f  adenovirus medi tated gene tran s fer 
are many . I n  r a t i o  to  the amount o f  adenovi rus produced, 
recomb inant vi rus cre a t i on and propagat ion i s  not l abor 
inten s i ve . Recombinant v i ruses depending on the t rans gene 
being exp r e s s ed ,  can be concentrated to t i t ers of greater 
than 1 0 1 1  part i c l e  forming uni ts  ( p f u )  per ml . 
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Addi t i ona l l y ,  unl i ke r e t rovi rus es , adenoviruses do not 
integrate into the ho s t  c e l l  genome114 • Non- integra t i on 
l imi t s  the i r  f e a s ib i l ity as a mechani sm for permanent and 
correct ive gene therapy11 5 , howeve r this is an advantage for 
cancer gene therapy . As a s a fety i s sue , there is a 
dimi n i shed probab i l i t y  for insert i onal mut agene s i s  to occur 
resu l t ing in t rans forma t i on of the target ce l l . 
Adenovi rus e s  a l s o have a wide host range1 10 and the re fore are 
s u i t ab l e  for gene t rans fer to numerous ce l l  typ e s . Al l o f  
these f e a tures ma ke adenovi rus a sui t ab l e  vector for cancer 
gene therapy . 
Glioma Tumor Model 
Ma l ignant gli omas have been chosen as a tumor mode l for 
d irect gene therapy for s everal reasons . These tumors tend 
to grow as s o l id focal tumor s  and are non-metastat ic4• 
Therefore , treatment of these pr imary CNS tumor s  before 
progre s s ive bra in inf i ltrat i on has the pos s ibility to result 
in cure with long term survival and decreased morbi dity . 
The prodrug GCV has very few systemic s ide effects at the 
dos e s  necess ary for its toxic metabo l ite to exert its anti­
neoplastic effect116 . Als o , GCV readi ly crosses the blood­
brain barrier97 • 103 
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Materials and Methods 
Cells : 
A l l c e l l s  were kept at 37°C and 5% C02 in Dulbecco's 
Mod i f i ed Eag l e  Medi um (DMEM) (Bi o f l u ids) supp l emen t ed wi th 
10% F e t a l  Ca l f  Serum (FCS) (Hyc l one), 2mM L-Glutamine and 
100 uni t s/ml Peni c i l l in and 100 ug/ml Streptomyc in (BRL) . 
Ce l l s  were pass aged when approximat e ly 70% c on f luent by 2 
minu t e  incubat i on in Tryps in/EDTA (BRL) f o l l owed by a s ing l e  
wash s tep in F C S  con t a in ing serum . Ce l l s  were then replated 
at 1/ 6 den s i ty in the appropr iate s ize t i s sue c u l ture 
d i she s . A l l  c e l l  l ines are descr ibed in the body of this 
manu s c r ipt . They were obtained f rom American Type Cul ture 
C o l l e c t i on (ATCC , Rockv i l l e ,  MD) except for the f o l l owing: 
C el l s  Type Spec i es Source 
9L G l i o sarcoma F i sher Rat Dr . E .  O ld f i e ld 
(NIH) 
RT2 As trocytoma F i s her Rat Dr . R .  Merchant 
(MCV) 
p494 G l i oma F i sher Rat Dr . R .  Touraine 
(NCHGR/NIH) 
Mesii-25 Meso the l i oma F i s her Rat Dr . R .  Toura ine 
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2 0 5  Fibrosarcoma C57Bl Mouse Dr . S .  Ros enberg 
( N I H ) 
KB Kidne y 
Animals: 
Human Dr . P .  S e th 
( N I H )  
Fema l e  Fisher 3 4 4  r a t s  obtai ned f rom the Na t i on a l  
Cancer I n s t i tute ( Frede r i c k ,  MD ) were u s e d  in a l l  s tudies . 
Anima l s  were housed in Bu i lding 4 9  o f  N I H  under Protocol #G-
9 4 - 8  and #G- 9 4 - 1 1  compl ying with N I H  approved st andards for 
the humane t reatment of anima l s . Al l anima l s  were under the 
supervi s ion of a s t a f f  ve ter inar i an .  Al l invas ive protoco l s  
were ve terinarian approved . The maximum a l l owed progre s s i on 
f o r  subcutaneous growing tumo rs was 4 0 0  mm3 • Supp o r t ive 
care was given when nece s s ary . 
Anima l s  were housed at a maximum o f  3 per cage and 
g i ven water and Purina Laboratory Chow ad l i bi t um .  
Immuno logica l l y  mature anima l s  o f  approxima t e l y  
1 5 0 - 2 0 0  g ( 8  wee ks ) were u s e d  i n  a l l  exper iment s invo lving 
subcutaneous tumo r t ransp l ant a t i on . I n  the se studi e s ,  a l l  
anima l s  were we i ght and age matched b y  experiment . 
Subcutaneous Tumor Transplantation: 
The abi l i ty o f  the various g l i oma c e l l  l ines to  produce 
subcutaneous tumo r was predetermined . To produce a tumo r o f  
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approximate l y  7 5  mm3 i n  7 days requi red a tumo r dose o f  3 X 
1 0 6 9L, and 2 X 1 06 RT2 ce l l s  1 1 7 . Ce l l s  we re inj ected in a 
vo lume o f  1 0 0  ul Pho sphate Bu f fered S a l ine ( PBS ) ( B i o f luids ) 
s ubcutaneous l y  on the r at do rsal surface j ust l ate ral to the 
mi dl ine us ing a 1 ml s yr inge and a 2 5  gauge needle . The 
needle was l e ft within the injection s ite for a few se conds 
and then pul l e d  out s l owl y in order to l imit needl e tract 
p l acement o f  ce l l s . A succes s fu l  inocul ation was dete rmined 
by formation o f  a r a i s e d  derma l we lt . Al l inj ections were 
per formed us ing a s epti c techni que . 
Recombinant Adenovirus Injection into Tumor and GCV 
AdnUnistration: 
The tumor area was prepared us ing ste r i l e  techn i que . 
The recomb i n ant adenovi rus was inj ected in a 1 0 0 ul vo lume 
o f  PBS with a 1 ml syr inge and 25 gauge needle . The needle 
was inserted s ubcutaneou s l y  1 em inferior to the tumor and 
p a s s ed i nto the mo st superior aspect o f  the tumo r .  The 
v i r a l  s o luti on was then inj ected as  the needle was 
r epos itioned within the tumo r ma s s  to insure maximum 
exposure o f  c e l l s . 
The h i ghest GCV do s e  to lerab l e  in 1 5 0 - 2 0 0 g rats without 
deve loping extens ive patho logy was 3 0 0  mg/ kg/day 1 1 8 . GCV 
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( S yntex Corpo ration ) ,  prepared in PBS on the da y o f  
inj e c t i o n ,  was admi n i s tered t o  anima l s  4 8  hours a fter tumor 
inj e c t ion . Anima l s  received 1 ml o f  GCV so lut i on containing 
1 5 0 mg/ kg/dose intraperi tone a l l y  twice a day for 5 da ys . 
Dai l y  inj e c t i ons were conduc ted 1 0  hours apart . GCV 
admin i s t r a t i on o f ten resul ted in renal and int e s t i nal 
patho l ogy accompanied by dehydration (NIH Pa tho l ogy 
Divi s i on ,  per sonal communi ca t i on ) .  Anima l s  s u f f e r ing from 
w e i ght l o s s  or di arrhea were given int rape r i toneal 
inj e c t i ons of 3 ml of normal sal ine ( B io fluids ) to augment 
f l u i d  l o s s . 
Animal Euthanasia and Spleen Removal: 
At var i ous t ime points a fter tumor tre atment ,  anima l s  
w e r e  euthan i zed in a C02 gas chamber . Sub s e quent l y ,  the 
sp leens were removed by a s ep t i c  techni que through a 
long i t udinal i nc i s i on on the an ima l's l e f t  dor s a l  sur face . 
The spl e ens were pl aced into DMEM- 1 0 %  FCS and the capsule 
b ro ken by fo rcep teas ing . Spl een ce l l s  were e l abo rated by 
mincing with the nub of a s t e r i l e  6 cc s yr inge and co l l ected 
i n  a 50 ml conical  tube . Red blood c e l l s  were r emoved by 
i ncub a t i on i n  5 ml of ACK l ys ing bu f fer ( N I H  med i a  uni t )  for 
5 minu t e s  a t  room t emperature . Ce l l s  were washed twice in 
PBS be fore addi t i onal manipulation . 
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Chromium Release Assay as a Measure of Cytotoxicity: 
Cytoto x i c ity was a s s e s s ed by the abi l ity o f  spleen 
e f fector ce l l s  to l ys e  various tumo r target cel l s . To 
dete rmine the amount o f  target ce l l  l ys i s , ta rget ce l l s  were 
labeled with 5 1C r . Log phase growing target ce l l s  were 
harvested from t i s sue culture dishes and s ingle c e l l  
suspen s i ons made . Ce l l s  were counted using a Coulter 
counte r and 5 X 1 0 5 ce l l s  were centri fuged at 8 0 0 g in DMEM-
1 0 %  FCS . The medium was aspi rated from the s e  pe l l ets and 
the ce l l s  were re suspended in the rema ining vo lume o f  
medium ,  approximate l y  5 0  ul . 2 0 0  uCi of  5 1 Cr ( Sodium 
Chromate in Ste r i l e  S a l ine; Ame rsham Biochemi ca l s ) s o luti on 
was added to target c e l l  suspens i ons and the c e l l s  were 
incubated for 2 hours in a 5 %  C02 i ncubator at 3 7°C .  During 
tar get cell incubation,  the various spleen e f fector ce l l  
di l utions whi ch wi l l  y i e l d  e f fector to tar get ratios o f  
1 0 0 : 1 , 5 0 : 1 , 2 5 : 1  and 1 2 . 5 : 1  were prepared by making a stock 
s o l ution o f  5 X 1 0 6  cells  per ml  and seri a l l y  d i l uting 1 : 2 . 
I n  a 9 6  we l l  U-bottom p l ate , 1 0 0  ul o f  the s e  s o l utions was 
added to the appropri ate we l l s  in trip l i c ate . T a rget cel l s  
were centr i fuged and washed 3 time s i n  DMEM-1 0 %  FCS . To 
reduce spontaneous leakage o f  51Cr the ce l l s  were i ncubated 
for an additiona l 4 5  minute s a fter the final wash . Target 
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c e l l s  were washed again i n  DMEM- 1 0 %  FCS and re suspended in 
1 0  ml . 1 0 0 ul o f  thi s  f i n a l  suspen s i on was added to a l l  
we l l s  conta ining e f fector ce l l s . Additiona l l y ,  1 2  we l l s  
recei ved target c e l l s  onl y .  These we l l s  serve to measure 
spontaneous and maximum l e a kage . The p l ates were i ncubated 
at 37 °C , 5 %  COz for 4 hours . One hour before harvesting 
1 0  ul of 8 %  Tr iton X- 1 0 0  was added to 6 we l l s  conta ining 
j ust target c e l l s  as  a me asure o f  max imum 5 1Cr l e akage . 
P l ates were harvested using a S katron harvesting s ystem 
( S katron , Virgini a ) . 5 1C r  release into supernatant was 
counted us ing an I CN Gamma Counter .  
C ytoto x i c ity as  mea sured by 5 1Cr rel ease from l abeled 
target c e l l s  was expr e s s e d  as  percent corrected l ys i s  for a 
concentrati on o f  e f fector cel l s  us ing the mean cpm ( counts 
per minute ) per tr ipl i cate we l l s . The fo rmula used was a s  
f o l l ows : 
Corrected % Lys i s  = 1 0 0  X ( e f fector c e l l  s ampl e  5 1Cr  
r e l eased - spontaneous target 51 Cr r e l e a s e d )  I ( max imum 
target 51 Cr  r e l e a sed - spontaneous target 51Cr r e l e a s e d )  . 
Secondary Stimulation Of Potential Cytotoxic Effector Cells: 
Optimum CTL l ys i s  usua l l y  requi res i n  vi t ro stimu l ation 
o f  pr imed e f fecto r c e l l s  with antigen . I n  th i s  proto co l ,  
e f fector c e l l s  were coincubated with i rradi ated ( 5 0 0 0  r ad )  
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tumo r  c e l l s  at a n  e f fector to s t imulator ratio o f  1 5 0 : 1 , 
5 0 : 1 , and 5 : 1 to  det e rmine optimum CTL act ivi t y  generat ion . 
E f fe c t o r  ce l l  c yto l yt i c  a c t i v i t y  was t i t rated aga i n s t  tumor 
s t imul a t i o n ,  and then the e f fects o f  low do se I L- 2  ( 1 0 
uni t s ) s t imu l a t ion were a s s e s s ed . I n  our tumo r s t imu l a t ion 
mode l , for the we a k l y  immunogenic 9L  tumor ,  l ow do s e  I L- 2  
was o ft en n o t  e f fect ive to gene rate s i gni f icant cyto l yt i c  
activi t y  from spl enocyt e s . P i lot s tudi es i n  o u r  l aboratory 
have shown increased cyto l y t i c  activity when e f fe c t o r  cel l s  
were cocul tured w i t h  s t imu l a tors a t  the prede termined 
opt ima l concen t ra t i on wi th 1 0 %  Rat T - s tim ( RTS , Fi sher 
Chemica l s ) . 
S econdary st imul a t i o n  o f  e f fector c e l l s  were ma inta ined 
in 24 we l l  p l at e s  wi th l ymphocytes at a concentrat i on of 5 X 
1 05 c e l l s /w e l l  and i rradi ated ( 5 0 0 0  rads ) tumo r ce l l s  a t  5 X 
1 0 5 c e l l s /we l l  for 6 days . 
Fluorescence Activated Cell Cytometry Analysis 
FACS ana l ys i s  were conducted according to the 
recommended procedure by Becton Dic kinson on a Becton 
D i c kinson FACScan . Ana l y s i s  was conducted using the Becton 
Dic kinson s o ftware L ys i s  I I  for the Hewl ett Packard o r  
Ce l l Qu e s t  f o r  the Macinto sh . 
Al l antibodies were obta ined f rom Pharmini gen . 
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Ant ibody s taining was conducted i n  s t aining med i a  ( PBS 
suppl emented with 0 . 5 % Bovine S erum Albumin and 0 . 2 5 %  NaN3 ) .  
1 X 1 06 cel l s  were cent ri fuged i n  Fal con 2 0 52 tube s ,  medium 
aspi rated and 0 . 5  ug o f  di rect l y  conj ugated ant ibody was 
added to the sma l l  vo lume of s t a ining medium rema ining . 
C e l l s  were p l aced on i ce for 2 0  minutes and then washed 
twice with 2 ml of st aining med i a . Fina l l y , cel l s  were 
ana l yzed by FACS anal ys i s  recording 1 0 0 0 0  event s .  I f  an 
indirect conj ugated antibody was used,  a f ter 1 wash in 2 ml 
o f  s t a ining medi a ,  the se cond antibody was added . Fo l lowing 
a 1 0  minute incuba tion,  cel l s  were washed twi ce in 2 ml 
s t ai n i ng medi a  and then ana l yzed . Non-ant ibody s ta ined 
ce l l s  were used to  gate rel evant event s .  As a negat ive 
cont ro l ,  cel l s  were s t a i ned with a s imi lar i s o t yp e  ant ibody 
di rected against a non- c e l l ular marker . 
E -Galactosidase Activity Determination and Measurement Of 
Recombinant Adenovirus Transduction Efficiency: 
I n  o rder to  determine the opt imal adenovi rus 
concentration for infectivity,  a recombinant adenovi rus 
exp r e s s i ng the E .  Co l i  nuc lear B - ga l actos idase gene (AV-
LacZ ) was created . By us ing B - ga l actos idase as a repo r t e r  
gene , infection o f  t a r g e t  ce l l s  with AV- LacZ c a n  be measured 
and corr e l a t ed to adenovi rus infectivi t y .  Th i s  a s s a y  re l i e s  
upon the hydro l y s i s  o f  f l uorescein di-B-D-ga l acto s i de 
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( FDG ) (Mo l ecular Probes ) ins ide ce l l s  w i th B - ga l actos idase 
a c t i v i t y  and the subsequent detection of f luore scein by FACS 
whi ch i s  the mo st sens i t ive method e x i s t ing . The method o f  
MacGrego r and No l an was used1 1 9 • B r i e f l y ,  ce l l s  were 
transduced i n  0 . 5  ml of DMEM- 2 %  FCS with di f ferent 
mul t ipl i c i t y  of infect ions ( MOi s )  of AV-Lacz . Thi r t y  sVI I 
hours l a t e r , c e l l s  were harves ted from t i s sue culture p l ates 
and l oaded w i th FDG by a 1 min .  hypo tonic shock a t  3 7°C .  
After 1 min,  C e l l s  were returned to  i s otoni c i t y  by di lut ion 
in i ce c o l d  media and kept on ice unt i l  ana l ys i s . 
Fluo r e s c e i n  passes through ce l l  memb ranes two hundred t imes 
faster at 3 7°C then at 4°C1 20 • By keeping the reac t i on on 
i c e ,  B - g a l actos idase a c t i v i t y  proceeds without l e a kage o f  
the de t e c t ab l e  cleaved f l uorescein mo l e cul e  a l l owing for 
d i s crimination between the B - ga l a ctos idase po s i t i ve and 
negative sub-popul at ions . I f  the FDG l ab e l ed cel l s  were 
brought t o  above 1 5°C ,  the f l uorescein l eaks through the 
c e l l  memb rane and into other ce l l s  inc luding B - ga l actos idase 
negat i ve cel l s  result ing in a popu l a t i on whi ch s t a ins 
homo geneous l y  for B - gal actos ida s e  expre s s ion when ana l y z ed 
by FACS 121 • To cont rol for this poss ibi l i t y,  the c e l l  l ines 
2 0 5  and 2 0 5  G 1NBGSVNA ( g i ft f rom J .  Rams ey,  N I H )  were used . 
The 2 0 5  G 1NBGSVNA i s  a mur i ne fibrosarcoma whi ch 
cons t i tut ive l y  expres ses the nuc l e a r  B - ga l acto s i da s e  gene 
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and po s i t ive l y  s e l ected i n  media cont a i ning 1 mg/ml G 4 1 8  
( BRL ) . 2 0 5  i s  the non- t ransduced parent l ine . The 2 0 5  
G 1 NBGSVNA c e l l  l ine s t a ins 1 0 0 %  pos i t ive for B - ga l actos idase 
gene exp re s s ion by FDG l oading and f l ow cytome t r i c  ana l y s i s  
( da t a  n o t  shown ) . By conducting mixture studies , the 
l eakage o f  fluorescein can be detected . 
Recombinant Adenovirus Creation: 
The method o f  Berkner was ut i l i zed1 22 • Cre a t i on o f  the 
adenovirus shut t l e  pl asmid pAVS 6 has been repo rted1 23 • 
Figure 1 d i agrams the s t eps in creation o f  the recombinant 
adenovi rus expre s s ing HSVTK . The pl asmid pAVS 6 -HSVTK ( gi f t  
o f  J .  R ams e y ,  N I H ) was l ine ari zed b y  No t I ( New Engl and 
B i o l ab s ) dige s t i on and cotrans fected on 2 9 3 ce l l s  w i t h  the 
Cla I cut fragment of Av- dl 3 2 7  ( g i ft of J .  Rams ey,  N I H ) . 
Two weeks l a t e r ,  infect i ous recomb inant adenovi rus vector 
p l a ques were pi cked,  expanded,  and scre ened for the HSVTK 
s e quence by polymerase chain reac t i on . Pos i t ive 
recomb inant s were grown on 2 9 3 ce l l s . AV-Lacz was s imi l a r l y  
created u s ing the B - galacto s i dase gene . 
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F i gure 1 - Cre a t i on of a Rec ombinant Adenovi rus Express ing 
The Herpes S implex Thymi dine Kinase Gene 
D i agram t i c  representa t i on of AV-HSVTK Crea t i on . The Plasmid 
pAVS 6-HSVTK was l inear i z ed by Not I res t r i c t i on enzyme 
dige s t i on and c o trans fec ted onto 2 9 3  c e l l s  with the C l a  I cut 
f ragment of Av-dl327 . 
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Recombinant Adenovirus Purification and Propagation: 
9 0 %  con f luent 2 9 3 ce l l s  were infected in DMEM- 2 %  FCS 
with the recombinant adenovirus at 1 - 1 0  p a r t i c l e  fo rming 
uni t s  ( p f u )  per ce l l . After a 1 . 5  hour incuba t i o n ,  the 
cel l s  were g rown in DMEM- 1 0 %  FCS and incubated at 3 7°C ,  5 %  
C02 unt i l  c ytopa thic e f fects were detected ( approxima t e l y  
2 4 - 3 6  hr ) . Ce l l s  we re harve s t ed from t i s sue culture dishes 
and cent ri fuged at 8 0 0  x g .  Cel l s  were l ysed by 4 cycles o f  
f r e e z ing and thawing and t h i s  crude v i r a l  l ysate was 
centr i fuged at 4 0 0 0  x g .  The supernatant was co l l ected and 
ove r l a i d  on a two s t ep C e s i um  Ch l o r i de ( C sCl , BioWh i t t aker 
Corpora t ion ) gradient ( d= l . 2 5 over d= l . 4 0 )  in u l t r a - c l e ar 
SW- 4 1  tube s . These tubes were then cent ri fuged using a SW-
4 1  rotor i n  a Beckman u l t racentri fuge for 1 hour a t  3 5 0 0 0  
rpm . The v i r a l  band a t  the interface was co l l e cted and spun 
on a s e cond 1 . 3 3 den s i t y  CsCl gradi ent for 1 8  hour s . The 
opa l e s cent virus band was co l l ected and d i a l yzed across  a 1 0  
rnM T ri s ,  1 rnM MgC l , 1 0 % g l ycerol bu f fe r . Vi rus was 
recovered f rom d i a l ys i s  bags and s t ored a t  - 7 0°C .  
Bystander Effect Measurement: 
The bys t ande r e f f ect was me asured by the ab i l i t y  o f  
various mixtures o f  HSVTK po s i t ive and HSVTK ne gat i ve cel l s  
to  p ro l i ferate i n  the presence o f  increas ing concentrat ions 
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o f  GCV . I n  the present s tudy, 7 0 %  conf luent cel l s  growing 
on 6 0  mm2 t i s sue culture dishes were washed once in PBS and 
then 1 ml o f  DMEM- 2 %  FCS containing the infect i ous dose o f  
v i rus e i ther AV-TK or AV- LacZ was added . After 1 . 5  hour s ,  
the DMEM- 2 %  FCS was aspirated into a b l each conta in i ng 
bucke t ,  ce l l s  were washed twice in PBS and then p l aced in 
DMEM- 1 0 % FCS . After 36 hour s ,  cel l s  were harve s t ed and 
mixed wi th non- t r ansduced c e l l s  to  y i e l d  mixtures conta ining 
1 0 0 %  t ransduced ce l l s ,  2 0 %  t ransduced cel l s ,  5 %  t r ansduced 
c e l l s  and 0 %  transduced ce l l s . Actual transduct i on 
percentage was de termined by FACS ana l ys i s  o f  B ­
g a l a c t o s i d a s e  expres s i on from the cel l s  infected wi th AV­
LacZ . 1 04 ce l l s  o f  the se various mixtures were added to 
i ndividu a l  wel l s  of 96 we l l  flat bot tomed plates  and a cross 
t i t r a t i on of 0 mM ,  0 . 5  mM ,  5 mM ,  and 5 0  mM GCV was added . 
The p l at e s  were p l aced in a 3 7 °C ,  5 %  C02 incuba to r .  4 8  
hours l a t e r  3H-Thymidine upt a ke was measured . 
Tritium Uptake Measurement: 
0 . 5  uCi o f  3H- thymidine ( NEN)  was added to each we l l  
and pl ates were i ncubated overni ght . The next da y ,  media 
was aspirated f rom we l l s  and the p l a t e s  were washed us ing a 
S ka t ron p l a t e  washer . 5 0  ul o f  5 0 %  PBS di luted t ryps in-EDTA 
was added to we l l s  and the plates  were harvested on a Tomtec 
Ce l l  Harve s t e r . E-plate f i l ters were dri e d  in a mi crowave 
for 3 minute s  and read on a LKB B-plate counter . 
Cell I rradiation: 
Ce l l s were prepared a t  a concentr a t i on o f  1 0 6 I ml in 
DMEM- 1 0 % FCS . The appropriate radi a t ion dos age was given 
us ing a 1 37C s  y- i rradi ator ( Bu i l ding 1 0 ,  N I H )  . 
Animal Immunization: 
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As a po s i t ive cont ro l , animal s  were immuni z ed against 
the var i ous g l i oma ce l l  l i nes by a modi f i c a t ion of  the 
method o f  Ho l l aday et a l . 4 8 . B r i e f l y ,  5 X 1 06 tumo r c e l l s  
were i r radi ated ( do s age given i n  t ext ) i n  a Ces ium 
i rradi a t o r . Thes e  tumo r c e l l s  were combined with 2 5  ug BCG 
and thi s ce l l - adj uvant mixture was admini s t ered o n l y  once to 
anima l s  by e i ther subcutaneous o r  intrape r i tonea l  inj ection . 
Limiting Dilution: 
T - l ympho cyt e s  were obt a ined f rom spl e ens o f  AV-TK 
treated-tumor abl ated anima l s  by column fractiona t i on 
(Accurate ) . A s t o c k  di l u t i on o f  ce l l s  was made a t  a 
concentr a t ion o f  2 0  c e l l s /ml . Al i quo t s  o f  2 0 0 ,  1 0 0 ,  5 0 ,  and 
5 u l / we l l  were p l aced in 96 w e l l  f l a t  bot tom p l at e s . The se 
d i l u t ions corre sponded to  4 ,  2 ,  1 ,  and 0 . 1  ce l l s / we l l  
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respective l y . Spl enocytes from naive cont rol anima l s  we re 
harve s t e d  and i rradiated at 2 5 0 0  rads . 2 5  ul o f  a 4 0 0  
ce l l s /ml concentrat ion o f  these c e l l s  was added t o  the 
previous l ympho cyte containing plates . S yngene i c  tumor 
c e l l s  were i r radiated ( 5 0 0 0  rads ) and 2 5  ul o f  a 4 0 0 ce l l /ml 
s to c k  s o l u t ion was added to each we l l . P l ates were 
i ncub a t ed a t  3 7°C and 5% C02 • Twent y  four hours l a t e r ,  2 5  
u l  o f  RTS ( Ra t  T - s t im,  Fi sher Chemi c a l  Company ) was added to  
e ach we l l .  Medium was repl aced every 3 days . I n  2 wee ks , 
ha l f  the numbe r  o f  cel l s  from each we l l  were trans ferred to  
fresh p l a t e s . 5 1Cr l ab e l ed s yngene i c  tumor ce l l s  were added 
to  each we l l  of the se mi rror p l a tes and chromium r e l e a s e  was 
measured in a four hour a s s ay . Chromium release o f  1 5 %  
greater than cont r o l  was con s i dered a pos i t ive reaction . 
P l a t e s  w i th a t  l e a s t  3 7 %  nega t i ve react ive we l l s  were 
con s i dered to  have been s t arted from a monoc l onal culture . 
React ive c l ones were harves t ed from the or igina l p l a t e s  and 
grown by repeated 5 day s t imul a t ion w i th i rradi ated 
auto l o gous tumor ce l l s . 
Statistical Analysis: 
Data was ana l yzed on an IBM compatible computer using 
P r i sm ( Gr aphPad Corpo ration,  San Di ego CA) , a sta t i s t i ca l  
ana l ys i s  s o f tware program . The appropriate test ut i l i zed i s  
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given i n  the body o f  the text in a s s o c i a t i on with the dat a . 
Adoptive Transfer: 
Adopt i ve t rans fer was conducted by inj e c t i on o f  bul k  
popu l a t i ons o f  spleen deri ved l ymphocyt e s  from donor anima l s  
to  recipi ent anima l s . Anima l sacr i f i ce and l ympho cyte 
derivation is previous l y  de scribed . Donor anima l s  are 
s tated i n  the body of the text . Recipi ent an ima l s  were 
naive 1 5 0 - 2 0 0 g  fema l e  Fisher rats  whi ch rece ived 
intraper i tonea l  inocul a t i ons of l ympho cytes in 3 ml of PBS . 
The numb e r  o f  l ymphocytes trans ferred i s  s tated in the 
accompanying f i gure legends . Adopt i ve t rans fer was 
conducted on the day of the donor anima l sacri f i ce . These 
l ymphocyt e s  were not in vi tro s t imulated prior to  t rans fer . 
Tumor Infiltrating Lymphocyte Derivation: 
Tumo rs were exc i s ed f rom animal s  us ing a s ept i c  
t echn i que . The s k in was care ful l y  d i s s e cted awa y f rom the 
tumor parenchyma . The remaining tumo r was cut into sma l l er 
f ragments and pl aced in a t r ip l e  enzyme solution cons i s t ing 
of Hanks Buf fered S a l t  Solution ( B i o fluids ) conta ining 0 . 1 % 
co l l a genase ( S i gma ) , 0 . 0 0 2 %  deoxyribonuclease ( S igma ) and 
0 . 0 1 %  hyaluronidase ( S igma ) . After 6 hours , the s ingle c e l l  
suspen s i on w a s  cent ri fuged at 1 0 0 0  X g and p l aced in fresh 
PBS . This s o l ut ion was care ful l y  ove r l a i d  on Lympho l yt e -M 
( Organon T e kn i c a ) and centri fuged a t  8 0 0  X g for 2 0  min .  
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The ce l l s  r emaining at the den s i t y  inter face were aspirated,  
washed 3 t imes i n  PBS and then s t a ined according to the 
s t ai ning p rocedure descr ibed previou s l y . 
Results 
For viral gene t rans fer to be e f f e c t ive , the 
recombinant v i rus mus t  have the abi l i ty to bind , penet ra t e , 
and e f f e c t ive ly expres s the transgene wi thout undo toxi c i ty 
to the t arge t c e l l . 
In the pas t f ew years , researchers have used 
rec ombinant adenoviruses t o  infect many c e l l  type s  inc luding 
neurons and g l ial c e l l s 124 , mus c l e125 , l iver123 , lung12 6 , and 
tumor c e l l s 127 . Whi l e the receptor seems to be ubiqu i t ous , 
i t s  expres s ion varies with c e l l  type111 . Mo s t  c e l l  types 
express adenovi rus receptors as exhibi ted by the i r  abi l i ty 
t o  be infec ted by adenoviruses with the exception o f  
lympho i d  l ineage c e l l s 128 . 
The gene trans f er or t rans f e c t i on e f f i c i ency i s  
dependent o n  the number o f  viral receptors and the 
i n f e c t i ous dose o f  virus 110 . The adenovi rus receptor has not 
been c loned , there f ore its expres s i on on cel l types c annot 
be quant i f ied . Ce l l s  such as HeLa , KB , and 2 9 3 s  are known 
to i n f ec t qu i t e  we l l  with wild type and recombinant 
adenovirus (data not shown ) . In o rder t o  det ermine 
43 
4 4  
t rans fect ion e f f i c i ency and gene express ion i n  a var i e t y  o f  
tumor t ype s ,  c e l l  l ines were infected with increas ing log 
dos e s  of a recombinant adenovirus express ing the 8-
g a l a c t o s i da s e  gene ( AV- LacZ ) .  8 - ga l actosidase a c t i v i t y  was 
then quan t i f i e d  by l oading wi th FDG , a f luore scent subs trate 
for the 8 - g a l actos idase enzyme and ana l yzed by f l ow 
c ytome t r y . The h i ghest dose used was a mul t ipl i c i t y  o f  
i n fect ion ( mo i ) o f  1 0 0 .  S a fety s tudies conducted during 
human c l inical t r i a l s  ut i l i z ing r ecombinant adenovi rus have 
been l imited to a t o t a l  dose of 1 010 p fu1 29 • Greater doses 
have the po t ent i a l  to l ead to acute toxici ty . We e s t imated 
that g i ven the number of c e l l s  in an advanced g l i oma i n  our 
s ubcutaneous mode l ,  an mo i o f  1 0 0  woul d  be the maximal 
t o l erab l e  dose . The resul t s o f  this  exper iment are given in 
Tab l e  I .  
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TABLE I - IN VITRO TRANSDUCTION EFFICIENCY OF CELLS 
INFECTED WITH A RECOMBINANT ADENOVIRUS VECTOR EXPRESSING THE 
a-GALACTOSIDASE MARKER GENE 
Percent Transduced ( % )  
MULTIPLICITY OF INFECTION 0 
Cell line Murine 
C 5 7 FB ( No rma l Fibrob l as t ) 0 
EL4  ( Leukemi c cel l )  0 
3 8  ( Co l on Adenocarcinoma ) 0 
2 0 5 ( Fibrosarcoma ) 0 
Rat 
9L ( G l i o s arcoma ) 0 
C 6  ( G l i oma ) 0 
RT2 ( G l i oma ) 0 
F 9 8  ( Gl i oma ) 0 
p 4 9 4  ( Gl i oma ) 0 
Di TNCL ( Tr ans formed As trocyte ) 0 
Mes I I  2 5  (Me sothe l i oma ) 0 
Fat 7  ( Na s a l  Carcinoma ) 0 
1 0  1 0 0  
6 . 3 0 1 8 . 1 2 
0 . 2 0 0 . 1 0 
4 . 2 7  2 8 . 6 4 
9 . 3 3 3 6 . 2 6  
1 . 0 0 2 7 . 5 1 
4 . 3 5 3 6 . 3 4 
7 . 7 0 4 1 . 5 8 
No t Done 4 0 . 1 5 
7 . 1 0 2 6 . 3 4 
5 5 . 1 7 1 0 0 . 0  
1 4 . 8 0 2 1 . 3 0 
6 . 4 0 5 4 . 7 0 
( Table I cont i nued on next page ) 
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TABLE I - IN VITRO TRANSDUCTION EFFICIENCY OF CELLS INFECTED 
WI TH A RECOMBINANT ADENOVIRUS VECTOR EXPRESS ING THE 
8-GALACTOSIDASE MARRER GENE 
Percent Transduced ( % )  
MULT I PLIC I TY  O F  INFECTION 0 1 0  1 0 0  
Cel l l ine Human 
KB ( Ce rvi cal Carcinoma ) 0 1 0 0 . 0  1 0 0 . 0  
DBTRG ( Human Gl ioblas toma ) 0 1 0 0 . 0  1 0 0 . 0  
NB4 ( Human G l i oma ) 0 1 0 0 . 0  1 0 0 . 0  
C e l l  l ine s were obta ined and grown a s  indicated in Materi a l s  
and Methods . 5 X 1 0 5 ce l l s  were p l a ted in 3 5  mm2 we l l s  o f  a 
6 we l l  p l a t e  and infected for 1 . 5  hours in 1 ml o f  DMEM- 2 %  
FCS wi th AV- LacZ a t  the given MO l . Ce l l s  were harve s t ed 3 6  
hours p o s t  infect ion and the B-gal actos idase act ivi t y  
measured a s  p e r  Mat e r i a l s  and Methods . Results  represent 
the comb i ned ave rage of 3 exper iment s .  
KB c e l l s  whi ch are known to  infect with adenovi rus at 
h i gh e f f i c i ency were used a s  a pos i t ive control to  i ns ure 
AV- LacZ i n fect ion . At a low mo i of 1 0 ,  these c e l l s  s t a ined 
1 0 0 %  p o s i t i ve indi cat ing t rans fer of the B - galactos idase 
gene by our recomb inant virus ( Tabl e  I ) . I n  comparing the 
e f f ect ivene s s  of AV-LacZ t ransduc t i o n ,  a few trends were 
not i ced . Rodent cel l s ,  e i ther murine or  ra t ,  infected w i th 
varying e f f i c iency depending on the ce l l  type . The l ymphoid 
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c e l l  l ine EL4 was not susceptible t o  adenovi rus infect ion . 
Thi s phenomenon was not l imited to  rodent cel l s . Human 
l ymphocyte ce l l  l ines a l s o  infected poo r l y  with 
adenov i rus128 • Of  the rat c e l l s ,  all infected with an 
e f f i c i ency of 2 5 %  - 4 0 %  a t  an mo i of 1 0 0 with the excep t i on 
o f  the SV4 0 T-ant i gen t rans formed rat a s t rocyte ce l l  l ine 
Di TNCL . SV4 0 genes are known to  compl ement adenovi rus 1 30 • 
Henc e ,  the increased gene expr e s s ion in this c e l l  l ine may 
be a cons e quence of SV4 0 upregulation of adenovi rus 
r ep l i ca t i on . Of  importance , the rat g l i oma ce l l  l ines 9L,  
RT2 and P 4 9 4  i n fected at leve l s  s u f f i cient to be va l id tumor 
mode l s  to paradigm the human s i tua t ion . 
A second not iceab l e  t rend was that human tumo r ce l l  
l ines infected with higher e f fi c i ency i n  compari son t o  the 
murine or  rat c e l l  l ines . This result was not unexpected . 
Murine adenoviruses have been i s o l ated which retain the 
abi l i t y  to  infect human c e l l s 105 • Ana l y s i s  of cap s i d  gene t i c  
s equences o f  murine and human adenovi rus shows s i gn i f i cant 
but no t comp l e t e  homo l ogy ( data not shown ) . Therefore,  AV­
LacZ , derived f rom a human adenovirus serotype was more 
l i ke l y  to  have greater a f f i n i t y  for the human receptor in 
con t r a s t  to  its rodent counterpar t ,  thus exp l a ining the 
d i f fe rence in t r ansduc t i on e f fi c i ency . 
I f  this  d i f ference in t ransduct i on e f fi c i ency i s  
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cons i s t ent for i n  si t u  transduct ion,  the s e  resu l t s  indicate 
that our rat  tumor mode l s  were acceptab l e  but unde rest imated 
the eventual t ransduct i on e f fi ciency whi ch could be expected 
with human tumors . The actual i n  vi vo s i gni f i cance o f  this 
d i f f erence i n  t ransduction e f f i c i ency was uncerta i n . Upon 
direct intratumo ral inj e c t i o n ,  the expo sure o f  c e l l s  to 
adenovi rus wi l l  be inve rs e l y  propo r t i onal to the d i s t ance 
from the s i t e  of adenovirus inoculat ion1 27 • Certain ce l l s  
wi l l  rece ive hi gh mo i o f  adenovi rus wh i l e  others may receive 
a s i gn i f i cant l y  l e s s e r  amount . Al s o ,  ce l l s  within a tumor 
foci  are more dens e l y  packed than in culture . Thi s ce l l  
dens i t y  may l imi t adenovi rus exposure and transduct i on 
e f f i c i ency . 
As stated ear l i e r ,  upon infect ion,  ce l l s  can harbor 
mul t ip l e  repl icates o f  the adenovi rus 1 31 • There fo r e ,  the 
l eve l of gene expre s s i on wi thin a given c e l l  i s  var i ed . I n  
order to ana l yze intrace l l u l a r  gene expre s s ion,  c e l l s  were 
i n fected wi th AV-LacZ and ana l yzed by f l ow cytome t r y . The 
FACS-Gal a s s a y  is uni que in that ce l l s  can be ana l yzed not 
j us t  for AV-LacZ infect ion but the a s s a y  al l ows for the 
l evel o f  gene expr e s s ion to be indi rect l y  quant i f i e d . This 
a s s a y  me asures the fluorescence o f  ce l l s  a fter convers ion o f  
a non- f luores cent sub s t rate by the adenovi rus t rans ferred B ­
galactos idase gene product to  a fluores cent marker1 32 • The 
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i nt ens i t y  o f  f l uores cence i s  an indirect corre l a t ion o f  B ­
g a l acto s i das e  gene expre s s ion . The t ransduct ion e f f i c i ency 
va lues measured i n  Table I repres ented the number of ce l l s  
showing po s i t ive fluorescence . I n  Fi gure 2 ,  gene expres s i on 
l eve l s  a s  indicated by f luore scence int ens i t y  for the human 
ce l l  l ine DBTRG are depi cted . Th i s  c e l l  l ine was cho s en 
becaus e i t  was 1 0 0 %  infected at a r e l a t ive l y  l ow do ses o f  
adenov i ru s  ( mo i= l O ,  Tab l e  I ) . There fore , incre as i ng the 
i n fe c t i ous dose of the recombinant adenovi rus ( mo i= l O O )  
a l l owed for compari son o f  gene expre s s ion wh i l e t r ansduct ion 
e f f i c i ency s t ayed constant . 
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Figure 2 - Comparative Fluorescence Intensity O f  Human 
Gl i oma Cell s  Transduced Wi th An Adenovi rus Vector Expressing 
The S -Galactosidase Gene And A Retrovi rus Transduced 
Fibrosarcoma 
Cel l Line Mean Fluorescent Intensity 
DBTRG - AV- LacZ MOI 1 0  2 4 3 . 0 4 
DBTRG - AV- Lacz MOI 1 0  8 1 0 . 7 8 
2 0 5  G lNBGSVNA 2 4 1 . 0 0 
Fluores cence o f  the ce l l  l ine DBTRG when loaded w i th FDG as  
indicated i n  Mater i a l s  and Methods i s  shown . Both dot plots 
( top row)  and f luore scence h i s tograms (middle row ) are 
g iven . Po s i t ive f luores cence for dot plots i s  indicated on 
the y- ax i s . C ytopl asmi c complexity i s  noted on the x-axi s . 
Mean fluo r e s cent intens i t y  i s  given in the tab l e . 
The s t aining contro l i s  given in the bot tom row whi ch 
shows fluorescence h i s t o grams o f  the c e l l  l ine 2 0 5  and 
2 0 5G l NBGSVNA . 
At an mo i o f  1 0 ,  1 0 0 %  o f  ce l l s  showed po s i t i ve 
f luores cence for B - gal actos idase activity ( Panel A ) . 
S imi l a r l y ,  a t  the higher infectious dose o f  virus (mo i = l O O ,  
Panel B ) , 1 0 0 %  o f  c e l l s  fl uoresced pos i t ive l y . However ,  the 
cel l s  were shi f ted upwards indicat ing greater fluores cent 
intens i t y .  This  incre a s e  i n  fluo rescence represents greater 
B - ga l actos i d a s e  act ivi t y  in these cel l s . Th i s  phenomenon i s  
a l s o  repres ented in the fluorescence h i s tograms ( mi ddl e 
row ) . Marker 1 (Ml ) represents b a s e l ine fluores cence o f  
uns t a ined c e l l s . Marker 2 (M2 ) encompasses the ce l l s  a fter 
FDG l o ading . The mean fluorescent inten s i t y  (MFI ) 
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demarcated by Marker 2 i s  given in the accompanying t abl e . 
I n  comparing the a t t a inab l e  MFI with that o f  a 1 0 0 %  
retrovi rus t r ansduced ce l l  l ine,  2 0 5  G l nBGSVNA, a mar ked 
di f f erence was s een . When 1 0 0 %  of cel l s  are r e t rovi rus 
transduced ( 2 0 5- G l nBGSVNA ) , the MFI was 2 4 1 .  This  l eve l o f  
B - galactosidase activi ty was comparab l e  t o  ce l l s  t r ansduced 
w i th AV-La cZ a t  a low mo i of 10 (MFI=2 4 3 ) . At an mo i o f  
1 0 0 ,  much greater enz yme activi t y  i s  exhibi t ed by the 
adenovi rus t r ansduced ce l l s  (MFI= 8 1 0 ) . 
The se data are s i gni f i cant for representing a d i s t inct 
advantage of adenovi rus vectors ove r retrovi rus vectors . A 
s ing le c e l l  may be mul t ip l y  infected wi th adenovi rus and ma y 
harbor 1 0 0 0  cop i e s  or greater o f  the recomb i nant vi rus 1 31 • 
I n  contrast  r e t rovi rus infect ivi ty i s  l imi ted by an unknown 
mechani sm to a few integrated cop i e s  per c e l l 80 • Thus , the 
l evel o f  adenovi rus medi ated gene express i on was not 
a t t a inab l e  w i th a ret rovi rus vector system .  The high copy 
number o f  adenovir ions permi ssab l e  wi thin a ce l l  a l l owed for 
greater gene expre s s i on whi ch for the recombinant adenovi rus 
express ing the HSVTK gene u l t imat e l y  a l l ows fo r greater 
convers i on of  the GCV prodrug to its toxic ana l o gue . 
I ncreased GCV tox i c i t y  i s  a d i s t i nct advantage o f  adenovi rus 
HSVTK gene t rans fer . For a l l  the c e l l  l ines repres ented i n  
T ab l e  I increas ing the adenovi rus infection do s e  increased 
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transduct ion unt i l  c e l l s  were 1 0 0 %  s aturated a fter wh ich an 
increase in gene expre s s ion was obse rved ( data not s hown ) . 
Desp i t e  the excel lent t ransduc t i on e f f i c i ency o f  human 
g l i omas by r ecombinant adenovirus ( Table I ) , ano ther 
pos s i b l e  l im i t a t ion to  viral gene therapy was the method o f  
adenovirus de l i very . HSVTK gene t rans fer confers 
suscept ibi l i t y  to  GCV tox i c i t y to tumo r and norma l c e l l s 1 33 • 
I n  o rder to  minimi ze tox i c i t y  to  norma l ce l l s ,  the pre ferred 
method of del ivery has been direct inj ect ion of re comb inant 
adenoviruses d i r e c t l y  into the tumor bed93 '  1 33 • Howeve r ,  
thi s  me thod i s  unl i k e l y  t o  infect a l l  ce l l s  within a tumor 
focus . I n  add i t ion,  our resul t s  from Tab l e  I ind i ca t ed that 
adenovirus gene t rans fer even at high mul tipl i c i t y  o f  
infect i ons was not adequate t o  con fer suicide gene 
suscept ibi l i t y  to  1 0 0 %  of g l i oma ce l l s  ( 9L and RT2 ) . As a 
viab l e  tumor t reatment regimen , e f fect ive gene t r ans fer to  
a l l  c e l l s  wi thin a tumo r focus must o ccur in order to  
prevent tumor reoccurrence . Trans fer o f  the HSVTK gene in 
combinat ion wi th GCV overcomes this  requi rement for gene 
t rans fer to  every tumor c e l l  by t a king advantage o f  the 
met abol i c  cooperativi t y  of tumo r ce l l s  by the bys t ande r 
e f fect1 34 • I n  1 9 9 0 ,  Moo l ten et al . showed e f fective tumor 
k i l l ing when a s  few as  1 0 %  o f  the tumo r ce l l s  exp r e s s ed the 
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HSVTK gene91 • The mechan i sm o f  GCV susceptib i l i t y  when only 
a fraction of  the tumor mass was gene t i ca l l y  modi f i ed was 
t hrough t rans f e r  of the toxic pho sphorylated GCV f rom a 
gene t i ca l l y  modi f i e d  ce l l  to  an adj acent non-modi f i ed ce l l  
through gap j un c t i ons ( s ee Literature Revi ew) . 
I n  Figur e s  3 and 4 ,  the bys t ande r e f fect a s s o c i ated 
wi th AV- TK gene t rans fe r  to  rat g l i oma cell  l ines is 
reported . The suscep t ib i l i t y  of these gliomas to bys t ande r 
k i l l ing i n  vi t ro was me asured by transduct ion o f  g l i oma 
c e l l s  ( mo i= 1 0 0 )  and then pl acing mixtures o f  transduced and 
nontransduced c e l l s  in increasing GCV concent r a t ions . C e l l  
p ro l i f e r a t i on w a s  me asured 4 8  hours l ater b y  3H - thymi dine 
upt a ke . Fo r a ce l l  l ine exhibi t ing a poor or  nonex i s tent 
bystander e f fect , the percent of cont rol pro l i f e r a t i on i s  
e qu i va l ent to  the percent o f  transduced ce l l s . Fo r examp l e ,  
a ce l l  mixture containing 5 0 %  HSVTK gene modi f i e d  c e l l s  
t rans l ates to  a 5 0 %  l o s s  o f  pro l i ferat ive pot en t i a l  s ince 
o n l y  gene t rans ferred ce l l s  are susceptibl e to GCV toxi ci t y . 
A s ingu l a r  prob l em w i th a s s e s sment o f  byst ander e f fect 
mediated by AV- TK gene t rans fer r e l a t ed to d i f feren t i a l  ce l l  
t ransduc t i on . A t  a n  mo i o f  1 0 0 ,  9L and RT2 a r e  n o t  1 0 0 %  
transduced ( Tab l e  I ) . There fo r e ,  the serial  di lutions o f  
adenov i rus t r an s duced cel l s  with unt ransduced ce l l s  was not 
d i r e ct l y  re f l ect i ve the actual percent o f  t ransduced ce l l s . 
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Ther e f o r e ,  t h e  actual number o f  transduced ce l l s  w i t h i n  a 
mixture was det e rmined by para l l e l  infections o f  ce l l s  w i th 
AV- LacZ a t  an mo i o f  1 0 0 .  Transduc t i on e f f i ciency was 
de t e rmined by FACS ana l ys i s  and bys t ande r mixtures were 
no rma l i zed u s i ng these data . 
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F igure 3 - In Vitro Bystander Ef fect 
Associated With AV-TK Infec t i on of 9L 
G l ioma C e l l s  
2 4 6 8 1 0  2 0  3 0  4 0  5 0  
GCV Conc entrat ion ( uM )  
5 6  
.... 1 9% AVTK 
-e- 4% AVTK 
...,._ 1 %  AVTK 
...... O% AVTK 
7 0 %  c o n f l u e n t  9 L  c e l l s  p l a t ed in 6 0  mm2 d i s h e s  were i n f e c ted 
w i t h  AV - TK at a mo i of 1 0 0 . 3 6  hou r s  p o s t i n f ec t i on ,  c e l l s  
were harve s t ed and s e r i a l ly di l u t e d  w i th non i n f ec t e d  9 L  
c e l l s . 1 0 4 c e l l s  we r e  p l a t ed in t r ip l i c a t e  in 9 6  we l l  f l a t ­
b o t t om p l a t e s  ( F a l c on ) and p l ac ed i n  i n c r e a s i ng l o g  
c on c en t r a t i ons o f  GCV . 3 6  hou r s  l a t e r , c e l l s  were pul sed 
ove r n i g h t  w i th 3H - Thym i d i ne and upt ake me a s u r ed p e r  
Ma t e r i a l s  a n d  Me thods . The d a t a  p o i n t s  r ep r e s en t  the c e l l  
mixture pr o l i f er a t i on va lue s norma l i z e d  t o  the i nd i v i du a l  
c on t r o l c e l l  m i x t u r e s  a t  0 u M  GCV . Ac t u a l  t ransduc t i on 
e f f i c iency was d e t e rmined by par a l l e l  i n f e c t i on s  o f  9 L  c e l l s  
w i t h  AV - L a c z  a t  a mo i o f  1 0 0  and de t e rmina t i on o f  
t r an s du c t i on p e r c e n t ag e  by f l ow c y t ome t ry per Ma t e r i a l s  and 
Methods . 
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Figure 4 - In Vitro Bystander E f fe c t  
Assoc i ated With AV-TK Infected RT2 
Gl ioma C e l l s  
2 4 6 8 10 20 30 
GCV Concentrat i on ( uM )  
40 50 
5 7  
..... 39% AVTK 
... 7. 5% AVTK 
..... 2% AVTK 
-+- 0% AVTK 
70% conf luent RT2 c e l l s  plated in 60 mm2 d i shes were 
infec ted with AV-TK at a mo i of 100 . 3 6  hours pos t  
infec t ion , c e l l s  were harves ted and ser i a l ly d i lu ted with 
noninfec ted RT2 c e l l s . 104 c e l l s  were plated in trip l icate 
in 96 we l l  f l at -bo t t om plates (Falcon ) and placed in 
increas ing log c oncentra t i ons of GCV . 3 6  hours later , c e l l s  
were pu l s ed overnight wi th 3H-Thymidine and uptake measured 
per Mater i a l s  and Methods . The data points represent the 
c e l l  mixture pro l i f erat ion values norma l i z ed to the 
individua l c ontrol c e l l  mixtures at 0 uM GCV . Ac tual 
transduc t ion e f f ic i ency was determined by para l l e l  
infect ions o f  RT2 c e l l s  w i t h  AV-Lacz a t  a moi o f  100 and 
determinat ion o f  transdu c t ion perc entage by f low cytometry 
per Mater i a l s  and Methods . 
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T h e  bystande r e f fect f o r  the 9 L  and RT2 g l i oma ce l l  
l ines was dependent o n  two factors ; the dose o f  GCV, and the 
percentage o f  transduced ce l l s  ( Fi gures 3 and 4 ) . 
Transduced ce l l s  were susceptible to  GCV toxi c i t y  a s  
indi cated by the de crease in pro l i f e r a t i on . The conve r s e  
w a s  a l so t rue in t h a t  l o s s  o f  pro l i f e r a t i on corr e l ated to  
ce l l  t r an s duct ion . The greater the proport ion o f  t r ansduced 
ce l l s  r e s u l t e d  in a greater the l o s s  of pro l i feration . C e l l  
mixtures cons i s t i ng o f  a greater prop o r t i on o f  t ransduced 
ce l l s  ( 9L - 1 9 %  t ransduced, RT2- 4 2 %  t ransduced)  were mo re 
suscep t i b l e  to  GCV tox i c i t y . I n  these group s ,  a mar ked 
decrease in c e l l  pro l i ferat ion was obse rved even at the 
l ower GCV concentrat ions ( 0 . 5  and 5 . 0  uM ) . 
I nt e re s t ing l y ,  both g l i oma c e l l  l ines exhibi t e d  a good 
bys t ander e f fect . A 6 0 %  or  greater loss of pro l i ferat ive 
abi l i t y  was seen w i th 9L and RT2 a t  the 5 uM GCV 
concen t r a t ion when as  few as  8 %  or  l e s s  o f  ce l l s  were 
transdu ced . I n  comparing the ce l l  l ine s ,  RT2 exhib i t e d  
greater bys t ander medi ated k i l l ing than 9 L . A t  a l l  do s e s  o f  
GCV, 9L  requ i red twice t h e  number o f  HSVTK gene exp r e s s ion 
to  exh i b i t  the loss of pro l i ferat ive poten t i a l  seen wi th 
RT2 . G i ven these dat a ,  both tumo r ce l l  l ines were poten t i a l  
mode l s  t o  further exp l o re the i n  vivo e f f i cacy o f  AV- TK . 
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The biodi spo s i t i on o f  GCV i n  rats  i s  unknown . 
Ther e f o r e ,  the i n  vi t ro dos e  corre sponding to i n  vi vo tumor 
expo sure to GCV i s  not ava i l abl e .  I n  humans , the FDA 
approved dose o f  GCV for the treatment o f  herpe t i c  
infect i ons i s  5 mg/ kg/day1 35 • Our resul ts  c l e a r l y  indi cated 
that tumor ki l l ing was enhanced by increasing GCV dose . I f  
HSVTK gene t rans fer i s  to  become a viable treatment option,  
the maximum t o l erab l e  dos e  of  GCV wi thout undo s ys t emic 
toxi c i t y  needs to  be de termined . 
For rat s ,  the maximum tolerable dose was det e rmined to  
be 300  mg/ kg/day when given intrape r i toneal l y  sp l i t  into two 
do s e s , 1 0  hours apart 1 1 8 . Woo and co l l eagues have shown 
e f fe c t i ve g l i oma regre s s ion with adenovirus medi ated HSVTK 
gene t r ans fer at do ses ranging from 5 0  mg/ kg/day to 2 0 0  
mg/ kg / da i36 • 
The abi l i t y  o f  AV- TK to  medi ate tumor regr e s s ion in 
di f ferent tumo r mode l s  was t e s t ed . AV- TK has been used to  
e f fect ively regress tumo rs in a var i e t y  o f  anima l mode l s  
inc luding g l i oma1 37 , l yrnphoma1 38 and me sothe l i oma1 39 • 
Intere s t ingl y ,  o f  the s e  s tudi e s ,  only in immunocompetent 
animal s  was AV- TK abl e to abrogate tumo rs . Treatment o f  
human tumors i n  nude anima l s  resul ted i n  a s i gni f i cant 
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decrea s e  in tumor volume , however ,  tumors continued to  
pro gre s s  a f t e r  the GCV admini stration period ended1 37 • I n  
anima l mode l s ,  repeat admi n i s tration o f  adenovirus vectors 
was not s ucces s fu l  due to generation of  a s t rong humor a l  
immune response a fter a s ingle virus exposure1 2 3 • B a s ed upon 
the obs e rva t i on that tumor el iminat i on was onl y  po s s ib l e  i n  
immunocompetent anima l s ,  t h e  ro l e  o f  the h o s t  immune 
re sponse in augment ing AV- TK medi ated tumor regr e s s ion was 
s tudied . 
The succe s s  o f  Woo and col leagues 1 37 in ear l i e r  
experiment s  w i t h  t h e  rat  g l i oma 9L prompted further 
research . Another rat g l i oma model desc ribed extens i ve l y  
i n  the l i t erature i s  RT2 48 • Both ce l l  l i nes expre s s  
ant igens to  whi ch c e l l u l a r  immune re sponses can be 
generated4 8 • Previ ous l y ,  the immunogen i c i t y  of rat g l i omas 
has been charact e r i zed by T I L  i so l ated f rom subcutaneous o r  
intracran i a l  impl ants o f  tumo r ce l l s 36 •  I n  these s tudi e s , 
ho s t  surviva l  and frequencies o f  CTL precursors correlated 
with tumor immunogeni c i t y  and the number o f  CTL precursors 
was r e f l e c t ive of  the c yt o l yt i c  immune re sponse generated 
a fter animal immuni zat ion . Therefore,  we eva luated the 
abi l i t y  of the se ce l l  l ine s to generate a c e l l u l a r  immune 
respons e a f t e r  immun i z a t ion o f  anima l s . D i f ferent 
immun i z at ion protoco l s  for generat ing immune responses were 
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t e s t ed i n  our l aboratory ( data not shown ) . Fi gure 5 s hows 
the c yt o l y t i c  respons e o f  spl enocyt e s  from anima l s  immuni zed 
s ubcutaneous l y  wi th 5 X 1 06 i rradiated tumor ce l l s  and 2 5  ug 
o f  Mycoba c t eri um Bovi s  ( BCG ) as an immune adj uvant . 
o'i? 
Figure 5 - Cel lular Immune Response 
From Anima l s  Immunized With Rat 
Gl ioma Ce ll Lines 
* 
Immun i z at i on Regimen 
* * *  
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F i sher rats were immuni zed by subcutaneous inj e c t i on o f  5 X 
106 g l ioma c e l l s  and 25 ug BCG or BCG a l one ( x-axi s ) . 
Target c e l l s  inc luded the syngene i c  F i s her rat der ived 9 L  
and RT2 c e l l s  and the a l l ogene i c  W i s tar-Furth r a t  der ived C 6  
c e l l s . Splenocytes f rom 3 anima l s  were harve s t ed 14 days 
a f ter immun i z a t ion and secondar i ly s t imu lated for 6 days in 
vi tro with irrad i a ted c e l l s  to which they they had been 
immuni z ed . Targe t c e l l  lys i s  (y-axi s )  was measured in a 4 
hour 51Cr release a s s ay . Lys i s  data i s  g iven for an 
e f fec tor to target ratio o f  100 : 1 .  Data was ana lyzed by 
Friedman t e s t  for repeated one way analys i s  o f  var i anc e . 
The 9L+BCG and the RT2 +BCG immun i z a t i on groups ( * )  were 
s igni f i cant (p<0 . 05 )  in c ompari s on to the BCG immun i z a t i on 
group . Add i t iona l ly ,  the RT2 +BCG group ( * * )  was s igni f icant 
( p<0 . 05 )  in c ompari s on t o  the 9L+BCG group . 
A very s trong cyto lyt i c  response ( 8 2 % ) at an e f fec tor 
to target ra t i o  of 100 : 1  was measured f rom RT2 immuni z ed 
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animal s .  I n  contras t ,  9L  immuni z ed anima l s  had a 
con s i derab l y  dimini shed r e sponse ( 1 8 % ) . No s i gn i f i cant 
c yt o t ox i c i t y  against g l i oma targets was measured by BCG 
immuni z a t i on a l one . The CTL response generated by g l i oma 
c e l l  immuni za t i on ( 9L or RT2 ) was MHC rest ricted a s  
det e rmined by the l a c k  o f  C 6  ( al l ogene i c  g l i oma ) t arget ce l l  
l y s i s  and direc t l y  r e f l ected the amount o f  CTL precursors 
generated f rom animal immuni zat i on ( data not shown ) . 
Di f ferent immuni z a t ion protoco l s  generated a s imi l a r  
di f feren t i a l  response w i t h  greater measurabl e C T L  re sponse 
f rom RT2 i nocu l a t ion in compari son to 9L exposure ( data not 
shown ) . 
To , further de termine parameters a f fect ing ant i gen i c i t y ,  
surface MHC C l a s s  I express ion w a s  quant i f ied . The MHC 
c l a s s  I gene products are known to p l a y  a role in tumor 
immuni t y .  Both qua l i tat i ve and quan t i t a t ive changes i n  MHC 
expre s s i on can result in a l te red ant i - tumor immune 
respons e s . Downregul a t i o n  o f  MHC C l a s s  I by v i r a l  gene 
products is known to enhance tumo r i geni c i t y  by abrogating 
CTL medi ated tumor reactivi t y .  The refore , quant i f icat ion o f  
MHC c l a s s  I expr e s s ion may further corrobo rate the increased 
immunogen i c i t y  of RT2 over 9L . I n  Fi gure 6 ,  the surface MHC 
C l a s s  I expr e s s i on o f  9L and RT2 is depi cted . 
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F i gure 6 - Surface MH C  C l a s s  I Expre s s i on o f  the 9 L  and RT2 
G l i oma Ce l l  L ine s 
9 L  - Un s t a ined 9L - S t a i ned 
M-IC9L0 0 1  
� �--------------, 
M-IC9L002 
� �--------------, 
0 0 
RT2 - Uns t a i n ed RT2 - S t a i ned 
M-ICRT200 1 
� .---------------. 
M-ICRT2002 
� �--------------. 
M2 
0 
G l i oma c e l l  l i n e s  grow i ng a t  7 0 %  c on f l uency were harve s t ed 
and s t a i ned w i t h  a F I TC l abe l l ed ant i body aga i n s t  MHC C l a s s  I 
gene produc t s  ( Pharm i n i ge n ) .  C e l l s  were immed i a t e l y  ana l y z ed 
by f l ow c y t ome t ry . Pane l s  on t h e  l e f t  repres ent un s t a i ned 
c e l l s . Pane l s  on the r i gh t  a r e  a f t er ant i body s t a i n i ng . 
F l uo r e s c e n c e  i s  d e t ec t ed on t h e  x - ax i s . Ml = g a t e  s e t  f rom 
u ns t a i ned c on t r o l  c e l l s .  M2 = M l  exc l u s i onary ga t e . 
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Previous l y  w e  repo rted that both 9L and R T 2  tumo r ce l l s  
expressed ant i gens against wh ich ce l l ul a r  immune responses 
were generated ( Fi gure 5 )  . Howeve r ,  these c e l l  l ines varied 
in the i r  ab i l i t y  to  gene rate react i ve CTL . A p o s s i b l e  
expl ana t i on c a n  be derived from comparing their surface MHC 
c l a s s  I exp r e s s i on ( Fi gure 6 ) . The MFI upon s t aining with 
ant ibody RT1A1 ( Pharmingen ) for MHC express ion was a lmos t  
three thous and t ime s greater for RT2 versus 9 L  ( Fi gure 6 ) . 
I nt e r e s t i n g l y ,  gene r a t i on o f  a cyto lytic response upon 
animal immun i z at i on corre l a t ed to the d i f ference in MHC 
expre s s ion . RT2 cytotox i c i t y  from immuni zed anima l s  was 
approx imat e l y  4 t ime s greater than measured for 9 L  a t  an 
e f fector to  t arget ratio of 1 0 0 : 1  in repeat exper iment s .  
Pos s ib l e  causes incl ude greater tumo r ant i gen presenta t i on 
in the context o f  MHC C l a s s  I ,  greater engagement o f  T-Cell  
receptors with MHC or  increased probab i l i t y o f  l ymphocyte 
and tumo r interaction . 
On the other hand, this  di f ference in ant i gen i c i t y  may 
not be r e l ated to MHC expres s i on . CTL activi t y  measurement 
i s  not an exact process and MHC expres s i on may vary by c e l l  
l ines i n  vi tro when grown i n  vi vo. Furthermore , genera t i on 
o f  a c e l l u l a r  immune response i s  dependent on many o ther 
factors including anti gen presenting cel l s . 
Regard l e s s  o f  the mechanism, RT2 was more immunogenic 
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than 9L  a s  de f i ned by greater i n  vi t ro CTL response 
generat ion . Given the d i f ferences , howeve r ,  the e f f i ci ency 
o f  AV- TK t re a tment to medi a t ed tumor eradication was s tudi ed 
us ing both c e l l  l ines . I t  was our opinion that the 
d i f fe rence in tumo r immunogen i c i t y  would a l l ow for a 
det e rminat ion o f  the r o l e  o f  host immuni t y  i n  tumo r 
regres s i on . 
I n  T ab l e  I I ,  AV- TK , mediated ab l a t ion o f  subcutaneous 
g l i omas was compared between ce l l  l ines and tumo r s i z es . 
TABLE I I  - SUBCUTANEOUS GLIOMA ABLATION EFFICIENCY BY 
ADENOVIRUS MEDIATED HERPES S IMPLEX THYMIDINE KINASE GENE 
TRANSFER AND GANCICLOVIR ADMINISTRATION 
Tumor : 9L RT2 
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Tumor 5 0 - 1 0 0  1 00 - 1 5 0  2 0 0 - 2 5 0  300-350 
Size mm3 mm3 mm3 mm3 
Treatment 
No Virus + GCV 0 / 9  0 / 9  0 / 6  0 / 6 
- GCV 0 / 9  0 / 9  0 / 6  0 / 6  
AV-Lacz + GCV 0 / 9  0 / 9  0 / 6  0 / 6 
- GCV 0 / 9  0 / 9  0 / 6  0 / 6  
AV-TK + GCV 0 / 9  0 / 9  0 / 6  0 / 6  
- GCV 1 4 / 1 5  * 1 5 / 2 9  1 2 / 1 2  * 9 / 9  * 
Sub cutaneous tumo rs o f  var i ous s i zes  sta ted above were 
inj ected with 2 X 1 09 p fu of the re combinant vi rus given in 
column 1 .  Control anima l s  rece ived sham inj ections o f  
veh i c l e . Thi r t y  sVI I hours a f t e r  inj ection,  certain groups 
of animal s  were given inj e c t i ons of GCV ( co lumn 2 )  as  per 
Mat e r i a l s  and Methods . Table values repre s ent anima l s  with 
comp l e t e  tumor ab l a t ion wi thout tumo r relapse as  d e f ined by 
non-palpab l e  tumor 3 months f rom the ini t i a l  date of tumor 
inj ect ion . Resul t s  are the comb i ned averages o f  3 
exp eriments . Resu l t s  in bold ( * )  are s t at i s t i c a l l y  
s i gni f i cant ( p< O . O S )  b y  chi square ana l ys i s  when compared to 
the treatment groups : AV- TK - GCV, AV- Lacz � GCV and No 
Virus + GCV . 
I n  Tab l e  I I ,  tumor abl a t ion was cont ingent on HSVTK 
gene t rans fe r  and GCV admin i s t r a t ion . Total ab l a t ion o f  
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tumo r s  d i d  n o t  corre late to  tumor regres s i on . In s i t u  
t r e a tment o f  subcutaneous tumors b y  int ratumo ral inj ect i ons 
of AV- TK fo l l owed by GCV admi n i s t ra t i on resu l t ed in tumor 
regre s s i on i n  1 0 0 %  o f  anima l s  ( data not shown ) . No tumor 
regre s s i on was s een in other control groups . Tumo r 
progre s s i on was not a l tered in anima l s  treated w i th AV-LacZ 
e i ther with o r  wi thout GCV treatment sugge s t ing that ne i ther 
adenovi rus o r  GCV is acut e l y  cyto s t a t i c  or cytotoxic 
independent l y .  Al s o ,  trans fer of  the HSVTK gene a l one (AV­
TK wi thout GCV ) was not s u f f i c ient for tumo r regres s i on or  
tumor e radi c a t ion . Tumor regr e s s i on was dependent on both 
thymidine kinase gene t rans fer and GCV admi n i s t r a t ion . 
Concerning tumo r abro gation,  o f  the anima l s  bearing 
1 0 0 - 1 5 0  rnrn3 9L tumo rs , 20 of 29 anima l s  init i a l l y  showed 
comp l e t e  tumor el imination but 5 anima l s  had tumo r 
reoccurrence . The final treatment e f f i c iency was 
approxima t e l y  5 0 % . Tumor s i z e did have a bearing on AV- TK 
t r e a tment e f fect ivenes s  for 9L tumors . Treatment o f  sma l l e r  
tumors ( 5 0 - 1 0 0  rnrn3 ) resu l t ed in a greater cure r a t e  ( 1 4 / 1 5  
anima l s )  whi ch was s t at i s t i ca l l y  s i gni f icant i n  compari s on 
t o  the other treatment groups wh i l e  the 5 0 %  tumo r abl a t i on 
e f f e c i ency for the l arger 9L  tumors was not . 
I n  cont r a s t ,  treatment o f  RT2 tumo rs was mo re 
e f f i cacious . Tumors o f  3 0 0 - 3 5 0 rnrn3 ( twice the s i z e o f  9L  
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tumo rs ) were e f fectively e l iminated wi th HSVTK gene transfer 
plus GCV admini s t r at ion . O f  the anima l s  with e l imina ted RT2 
tumo r s , r e l apse was never observed . There fore , AV- TK plus 
GCV was mor e  e f fect ive for the t reatment of the mor e  
immunogen i c  R T 2  g l i omas . 
I n  Fi gure 7 ,  a s e r i e s  o f  pane l s  i l lustrat ing the course 
o f  an exceptiona l l y  l a rge RT2 tumo r that regre s s e d  upon AV­
TK and GCV admi n i s t r a t ion i s  shown . 
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Figure 7 A  - RT2 Tumor Regre s s i on After Treatment W i th AV-TK 
I ntratumo ral Inj ect ion And GCV Admin i s t ra t i on 
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2 X 1 06 RT2 g l i oma cel l s  were inj ected subcut aneous l y  on the 
do r s a l  back 1 em from the midl ine . 2 1  days l a t e r ,  t h i s  
tumor o f  app roxima t e l y  1 8 0 0  mm3 w a s  inj ected w i t h  2 X 1 0 9 
p fu o f  AV-TK in 1 0 0  u l  PBS . 4 8  hours a fter inj e c t i o n ,  this  
animal was given intrape ri toneal i nj ections o f  1 5 0  
mg/ kg / do s e  twice a day,  1 0  hours apart , for 5 da ys . 
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Figure 7 B  - RT2 Tumo r Regre s s ion After Treatment W i th AV- TK 
I n t ra tumor a l  Inj e c t i on And GCV Admin i s t ra t i on 
2 X 1 06 RT2 g l i oma cel l s  were inj ected subcutaneous l y  on the 
dor s a l  back 1 em f rom the midl ine . 2 1  days l a t e r ,  this  
tumo r  of  approxima t e l y  1 8 0 0  mm3 was inj ected wi th 2 X 1 09 
p fu o f  AV- TK i n  1 0 0  ul PBS . 4 8  hours a fter i nj e c t i o n ,  this  
animal was given intraperi toneal inj ections of  1 5 0  
mg/ kg / do s e  twice a day ,  1 0  hours apart , for 5 days . This 
photograph was t a ken 1 wee k  after AV- TK i nj e c t i on and 3 days 
f rom the end of the GCV admi n i s t ra t i on period . 
7 1  
Fi g u r e  7 C  - RT2 Tumo r R e g r e s s i o n  A f t e r  T r e a tment W i t h  AV- T K  
I n t r a t umo r a l  I n j e c t i on And GCV Admi n i s t r a t i o n  
2 X 1 0 6 RT2 g l i oma c e l l s  w e r e  i n j e c t e d  s ub c u t an e o u s l y  o n  t he 
do r s a l  b a c k  1 em f rom t h e  m i d l i n e . 2 1  days l a t e r ,  t h i s  
t umo r o f  app r o x i ma t e l y  1 8 0 0  mm3 was i n j e c t e d  w i t h  2 X 1 0 9 
p f u  o f  AV- T K  i n  1 0 0  u l  PBS . 4 8  hours a f t e r  i n j e c t i on ,  t h i s  
an ima l w a s  g i v e n  i n t r ap e r i tone a l  i n j e c t i o n s  o f  1 5 0 
mg/ k g / do s e  t w i c e  a d a y ,  1 0  hours apar t ,  f o r  5 d a y s . T h i s  
pho t o g r aph w a s  t a k e n  3 w e e k s  a f t e r  AV- T K  i n j e c t i o n  and 1 8  
days f r om t h e  end o f  t h e  GCV adm i n i s t r a t i o n  p e r i o d . 
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F i g u r e  7 D  - RT2 Tumo r R e g r e s s i o n  A f t e r  T r e a tment W i th AV- T K  
I n t r a t urno r a l  I n j e c t i o n  And GCV Adm i n i s t r a t i o n  
2 X 1 0 6 R T 2  g l i oma c e l l s  w e r e  i n j e c t ed s ubcutaneo u s l y  on t h e  
do r s a l  b a c k  1 e rn  f r om t h e  m i d l i n e . 2 1  days l a t e r ,  t h i s 
t umor o f  app r o x i ma t e l y  1 8 0 0  rnrn3 w a s  i n j e c t e d  wi t h  2 X 1 0 9 
p f u  o f  AV- T K  i n  1 0 0  u l  PBS . 4 8  hours a f t e r  i n j e c t i o n ,  t h i s  
a n i m a l  w a s  g i ven i n t r ape r i t one a l  i n j e c t i on s  o f  1 5 0 
rng/ k g / do s e  t w i c e  a d a y ,  1 0  ho u r s  ap a r t , f o r  5 d a y s . T h i s  
pho t o g r aph w a s  t a ke n  4 w e e k s  a f t e r  AV- T K  i n j e c t i o n  a n d  2 5  
days f r om t h e  end o f  t h e  GCV adm i n i s t r a t i o n  p e r i o d . 
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The tumor represented was o r i gi na l l y  1 8 0 0  rnm3 ( Fi gure 
7A) . Thi s anima l was part o f  an exper iment evaluat ing 
s urviva l of rats with subcutaneous tumors . The r e fore , the 
tumor s i ze was permi s s ib l e  under veterinarian approved 
exemp t ion to  our e a r l i e r  mandate to  sacri f i ce anima l s  when 
tumor s i ze s  were greater than 4 0 0  rnm3 • One week f o l l owing 
AV-TK t re atment and 3 days f o l l owing the final GCV 
inj e c t i o n ,  the tumo r regre s s ed cons i derabl y .  The tumo r mas s  
was e rythematous and i n f l amed ( Fi gure 7B ) . However ,  a 
maj o r i t y  o f  the tumo r was s t i l l  present . In  Figure 7 C ,  the 
tumor at 3 weeks from adenovirus inj e c t i on is dep i cted . The 
tumor mas s  further regr e s s ed to  become scar t i s sue and onl y 
a r e s i dual ulcerated l e s i on was visibl e . After t i s sue 
r emode l ing,  this scar rema ined as  a granulomatous l e s i on 
( Fi gure 7 D ) . 
As depi cted in Figure 7 ,  r e s i dual tumor rema ined at the 
end o f  the GCV dos ing period ( Fi gure 7B and 7 C )  and was 
present as far as  3 weeks a f ter AV- TK inj ection into the 
tumo r . Many anima l s  with tumors of this s i ze continued to 
exh ib i t  tumo r regres s ion and eventual l y  resu l t ed in comp l e t e  
tumor e l imina t i on ( data n o t  shown ) . The cours e  o f  this  
tumor s e rves to  i l lustrate the invo lvement o f  ho s t  immuni t y  
in augment ing tumo r regres s i on . 
Us i ng radi o l abeled GCV in bys t ander e f fect s tudi e s ,  H .  
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I sh i i  has  s hown that GCV e f fects i n  vi t ro occured very 
r ap i d l y1 4 0 •  Trans fer o f  the phosphorylated GCV met abo l i t e s  
o ccurs i n  a mat t e r  o f  hour s . I f  thi s datum i s  extrapo l a t ed 
to  the i n  vi vo s i tua t ion,  a s  a conservat ive e s t imat e  one ma y 
a s sume that any t ransduced c e l l  has been k i l led by 7 days 
f rom the end of the GCV dos age period ( approx ima t e l y  1 0  days 
f rom the t ime o f  adenovirus administrat ion ) . The serum 
h a l f- l i fe o f  GCV i s  approxima t e l y  6 hours 1 35 • Therefo re , any 
further ki l l ing of r e s i dual tumor a fter this period cannot 
be exp l a ined by GCV medi ated toxici t y .  An exp l anat i on o f  
this  phenomenon must depend on host augmenta t i on o f  tumo r 
l ys i s . P r i o r  s tudies in athyrnic nude mice showed 
s i gn i f i cant regress ion of human t ransp l anted tumo r c e l l  
l ines a fter AV- TK and GCV t reatment 1 37 • Howeve r ,  desp i t e  a 
s ub s t ant i a l  decrease in tumo r vo lume , r e s i dual tumo r 
rema ined and eventua l l y  progre s s ed . Treatment o f  tumor s  in 
immuno competent anima l s , has shown increased infi l t r a t i on o f  
macrophages and l ymphocyt e s  a t  the inj e c t i on s i t e14 1 • The se 
r e su l t s  indicate that i n  vi vo bys tander k i l l ing in the 
absence o f  comp l e t e  tumor t ransduction ma y have an immune 
component . Our wor king hypothe s i s  was that AV- TK and GCV 
reduced the tumo r burden s u f f i c i ent l y  al l owing for a host 
ant i - tumor immune response to  be generated ( Fi gure 7 ) . To 
test this hypothe s i s ,  the abi l i ty of AV-TK with GCV to  
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medi a t e  9L  tumor regre s s ion in nude rats  was eva luated . 
TABLE I I I  - SUBCUTANEOUS 9L GLIOMA ABLATION E FFICIENCY BY 
ADENOVIRUS MEDIATED HERPES S IMPLEX THYMIDINE KINASE GENE 
TRANSFER AND GCV ADMINISTRATION 
Treatment Prodrug Animal s Rejecting 
Admini s tration Tumor 
AV- TK + GCV 0 / 1 1  
- GCV 0 / 3  
AV- LacZ + GCV 0 / 3  
Veh i c l e  + GCV 0 / 3  
Veh i c l e  - GCV 0 / 3  
Subcutaneous 9L  tumo rs were grown by inocul at ion o f  3 X 1 06 
9L c e l l s  on the do r s a l  sur face o f  nude rats . Thes e  tumors 
( 1 0 0 - 1 5 0  mm3 ) were inj ected with 2 X 1 09 p fu of the 
recomb inant adenovi rus s tated in the l e ft column in a total  
vo l ume of  1 0 0 u l  PBS . Anima l s  were subsequent l y  dosed with 
GCV a s  stated i n  the Mate r i a l s  and Methods for 5 days . 
Resul t s  represent the number o f  anima l s  with comp l e t e  tumor 
abl a t i on de fined as  non-palpab l e  tumor as determined 2 
months f rom the t ime o f  adenovirus i noculation . Re s u l t s  are 
not s t a t i s t i ca l l y  s i gni f i cant in compari son to each other . 
Tumor s  were started on the do r s a l  surface o f  anima l s  by 
9L c e l l  i no cul a t ion . After 21 days , tumors of approxima t e l y  
1 0 0 - 1 5 0  mm3 w e r e  t r e a t e d  w i t h  re combinant vi rus o r  veh i c l e  
inj e c t i on and then s eparated i n t o  groups receiving e i ther 
GCV or PBS inj e c t i ons . Anima l s  were observed for 4 months 
and tumor volume s were measured on a weekly bas i s . 
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I n t e r e s t ingly,  anima l s  receiving AV- TK inj e c t i on 
coup l ed w i th GCV administration showed part i a l  tumor 
regr e s s ion ( da t a  not presented ) . Tumors dimini shed in 
volume to  approxima t e l y  50% of the i r  or i ginal s i ze over the 
f i r s t  2 weeks f rom the t ime of adenovi rus inj e c t i on . 
However ,  a f t e r  this i n i t i a l  period o f  tumor regres s ion,  
tumor vo l umes proceeded to  increase over the sub s e quent 
weeks nece s s i t a t ing anima l euthanas i a  a fter 2 months . I n  
con t ras t ,  tumo r regress ion was not obs e rved in the other 
contr o l  groups . Tumor volumes in the other groups increased 
over t ime unt i l  anima l s  were s acri fi ced . 
S imi l a r  to  the obs e rvat i ons made in immunocompetent 
anima l s  ( Tab le I I ) , tumo r regress ion was dependent on HSVTK 
gene t rans fer and prodrug ( GCV ) admin i s t ra t i on . Qui t e  
d i f fe rent l y  however ,  treatment o f  s ubcut aneous tumors i n  
the s e  athymi c anima l s  b y  AV-TK and GCV w a s  ine f fe c t ive in 
medi a t ing compl ete tumor e l imina t i on ( Tab l e  I I I ) . Whereas 
in our e a r l i er exper iment s ,  tumors of the same s i z e were 
abl a t e d  by AV- TK and GCV treatment in immuno competent 
anima l s  ( Table I I ) , none o f  the 9L tumors of a thymi c anima l s  
were eradi cated by HSVTK gene trans fer . Thi s di f f erence in 
treatment e f f i c i ency was att ributed to the l ack of an ant i ­
tumor immune response i n  the a thymic anima l s . The se resu l t s  
i ndi cate t h e  importance o f  the immune response i n  
f a c i l i t a t ing tumor abl a t i on . In vi tro, 9L ce l l s  are 
considered t o  have a r e l a t i ve l y  good bystander e f fect 
( Fi gure 3 )  med i a t ed by the t rans fer of toxic GCV 
met abo l i t e s . The poor t reatment e f f i c i ency i n  vi vo o f  9L 
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tumors sugge s t s  that upon intratumoral inj ection o f  AV- TK, 
the GCV a s s o c i a t ed bys t ander e f fect was insuf f i c i ent to  
result i n  comp l e t e  tumor regre ss ion . In vi vo, HSVTK gene 
t rans f e r  needed to  be augmented by hos t  immuni t y  in order to 
be maxima l l y  e f fect ive as  a treatment regimen . 
To further s tudy the invo lvement o f  host immuni t y  in 
tumor eradi c a t i on ,  anima l s  with ab la ted g l i omas were given 
secondar y  cha l l enges with lethal ( 3  X 1 07 ) and tumo r i geni c  
( 3  X 1 0 6 ) do s e s  o f  tumo r ce l l s  b y  inocu l a t ion on the 
oppo s i t e  f l ank ( T ab le I V ) . As a pos i t ive control for tumo r 
forma t i o n ,  n a i ve anima l s  were s imi l a r l y  gi ven tumor 
cha l l enges . 
TABLE IV - RESISTANCE TO TUMOR FORMATION IN ANIMALS 
W I TH ABLATED SUBCUTANEOUS GLIOMAS BY AV-TK AND GCV 
ADMINI STRATION 
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Ini tial Secondary Dose Animals Forming 
Ablated Tumor Tumor Tumor 
Challenge 
9L 9L 3 X 1 06 0 / 1 5  * 
3 X 1 07 0 / 1 2  * 
Me s i i 2 5 3 X 1 06 3 / 3  
RT2 RT2 3 X 1 06 0 / 8  * 
3 X 1 07 0 / 6  * 
Mes i i 2 5  3 X 1 0 6 3 / 3  
None 9L 3 X 1 0 6 3 0 / 3 0  
3 X 1 0  7 1 5 / 1 5  
RT2 3 X 1 0 6 1 2 / 1 2  
3 X 1 07 1 2 / 1 2  
Mes i i 2 5  3 X 1 0 6 3 / 3  
Anima l s  with approxima t e l y  2 0 0  mm3 tumo rs ( co lumn 1 )  abl ated 
by AV- TK inj ect ion and GCV admini s t r a t i on per Mat e r i a l s  and 
Methods were i noculated with tumo r i genic or l e thal dos e s  
( co l umn 3 )  o f  rat g l i oma ce l l s  or the s ygene i c  mesothe l i oma 
ce l l  l ine Mes i i - 2 5  on the oppo s i t e  f l ank f rom the ini t i a l  
tumor s i t e . T h i s  secondary cha l l enge o f  tumor ce l l s  was 
given at 1 month from the t ime of AV-TK inj ection of the 
i n i t i a l  ab l ated tumor . The se anima l s  were obs e rved for 3 
months . Tumo r  forma t i on ( co lumn 4 )  was de fined a s  pa lpab l e  
tumor at l e a s t  1 month from the t ime o f  secondary tumor 
inocu l a t ion . Results represent the comb ined values o f  2 
exper iment s .  Resul t s  i n  bo l d  ( * )  are s t at i s t i ca l l y  
s i gni f i cant ( p < 0 . 0 0 1 )  by chi - s quare anal ys i s  when compared 
to naive con t r o l  anima l s  cha l l enged with e i ther 9L or  RT2 
tumors . 
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I n  Tab l e  I V  anima l s  with a n  abl ated s ubcutaneous 9L or  
RT2 g l i oma generated an ant i - tumor immune re sponse capabl e  
o f  prevent ing engraftment o f  tumor c e l l s . 1 0 0 %  o f  anima l s  
wi th an ab l a t e d  g l i oma by AV-TK and GCV treatment rej ected a 
s econdary inoculum o f  tumor ce l l s . Howeve r ,  this ant i - tumor 
r e sponse was tumor spe c i f i c  as  de termined by the secondary 
chal l enges w i th the MHC C l a s s  I expres s ing s yngene i c  
mesothel i oma c e l l  l ine MES I I - 2 5 . Anima l s  w i t h  previ ous l y  
ablated 9 L  o r  RT2 tumo rs f a i l e d  t o  rej ect the me sothe l ioma 
c e l l  l ine and were only able to rej ect tumo r c e l l s  to whi ch 
they were p revious l y  exposed ( Tabl e  IV)  . Deve l opment o f  
ant i - tumor immuni t y  was not cont ingent o n  the immuno geni c i t y  
o f  the ini t i a l  g l i oma as  anima l s  w i t h  abl a t ed 9L  tumors were 
a s  res i s t ant to  secondary tumor chal l enges as  the anima l s  
cured o f  RT2 . Anima l s  have been obs e rved for over 1 year 
s ince the t ime of AV- TK treatment and a l l  anima l s  rema in 
tumor free . These anima l s  are continuing to  be obs e rved . 
Nex t ,  the kine t i c s  o f  tumor immuni t y  was s tudi ed . 
Particu l a r l y  o f  interest was the time period over whi ch 
the s e  anima l s  exhib i t ed tumor immuni t y .  I n  the previous 
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experiment anima l s  were chal l enged with tumo r ce l l s  1 month 
a fter t r e a tment of the ini t i a l  tumor . To addr e s s  if the 
obs e rved ant i - tumo r response was po s s ib l y  l imi ted in i t s  
t ime cour s e ,  anima l s  w i th ab lated tumors were s e conda r i l y  
cha l l enged w i th tumo r ce l l s  as  i n  the previous exper iment . 
Howeve r ,  the t iming o f  the seconda ry tumor cha l l enge was 
var i ed from the t ime of i n i t i a l  tumor eradicat ion . 
TABLE V - RE S I S TANCE TO TUMOR FORMATION IN ANIMALS WITH 
ABLATED SUBCUTANEOUS GLIOMAS BY AV-TK AND GCV ADMINISTRATION 
Ini tial Secondary Animals Animals Animals 
Ablated Tumor Forming Forming Forming 
Tumor By Chal l enge Tumor Upon Tumor Upon Tumor Upon 
AV-Tk And Rechallenge Rechal lenge Rechal l enge 
Gcv At 1 Month At 2 Months at 6 Months 
Treatment 
91 91 0/15 * 0/3 * 0 / 9  * 
RT2 RT2 0/8 * 0 / 3  0 / 6  * 
None 91 1 5 / 1 5  1 5 / 1 5  1 5 / 1 5  
None RT2 3 / 3  6 / 6 6 / 6  
Anima l s  wi th approxima t e l y  2 0 0  rnrn3 tumors ( co l umn 1 )  ab l a t ed 
by AV-TK inj e c t i on and GCV admi n i s t r a t i on per Mate r i a l s  and 
Methods were inoculated with tumo r i genic do ses of the tumo r 
ce l l s  to  wh i ch they had previou s l y  cured ( co lumn 2 )  on the 
oppo s i t e  f l ank f rom the i n i t i a l  tumo r s i te . This secondary 
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cha l l enge o f  tumor c e l l s  was given at 1 month ( co l umn 3 ) , 2 
months ( co l umn 4 )  o r  6 months ( column 5 )  from the t ime o f  
AV- TK inj e c t ion o f  the ini t i a l  tumo r . These anima l s  were 
observed for 3 months . Results ( co l umn 3 ,  4 ,  and 5 )  
rep r e s ent tumor format i on a s  de f ined by palpab l e  tumor at 
least l month f rom the t ime of secondary tumor inj e c t ion . 
Resu l t s  in bo l d  ( * )  are s t a t i s t i ca l l y  s i gn i f i cant ( p < 0 . 0 5 )  
b y  chi square anal ys i s  when compared t o  the i r  corre sponding 
cont ro l s  cha l lenged with the s ame tumor ce l l  l ine . 
Anima l s  exhib i ted l ong s tanding tumor immuni t y .  Fo r 
peri ods up to  6 months a f t e r  abl at i on o f  the o r i ginal tumor , 
anima l s  rej ected engr a f tment o f  the auto logous tumo r ce l l s  
( Table V) . Thi s l ong term tumor immunity was not dependent 
on the immunogen i c i t y  of the or i ginal tumo r as 9L  ablated 
anima l s  rej ected seconda ry tumo r engraftment as  we l l  as RT2 
abl a t e d  anima l s . Long term tumo r re s i s t ance i s  s i gn i f i cant 
s ince in mo s t  c a s e s  o f  tumo r reoccurrence the secondary 
tumor focus i s  a consequence of seeding f rom the o r i ginal 
s i t e . As tumo r me t a s t a s e s  o ften share the s ame ant i genic 
ep i t ope , deve lopment of tumo r immuni t y  fol lowing tre atment 
o f  the ini t i a l  tumo r may p revent d i s t ant met a s t a s e s . This 
hypothe s i s  i s  current l y  being inve s t igated . 
Gi ven AV- TK t reated 9L  ablated an ima l s  to rej ected 
engra f tment o f  the minimum tumor forming dose or  ( 3  X 1 0 6 
ce l l s ) or  a l ethal dose ( 3  X 1 07 cel l s )  o f  tumor c e l l s  for a 
period o f  a t  l e a s t  6 months from the t ime o f  o r i g inal tumo r 
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expos ure , invo lvement o f  the hos t  immune response was 
indi cated . The re are three maj or types o f  l ymphocytes 
reported t o  have cytotoxic ant i - tumo r a c t ivity both i n  vi t ro 
a n d  i n  vi vo . These c e l l  popul a t i ons are NK ce l l s , LAK c e l l s  
and CTL1 4 • 
NK c e l l s  are no rmal c i rculat ing ce l l s  invo lved i n  
immune surve i l l ance 1 4 . Thi s group o f  l ymphocyt es h a s  the 
i nt r ins i c  abi l i t y  to  recogn i z e  and des t roy tumo r cel l s  
wi thout previous exposure . In humans they are CD3 - ,  CD1 6+ , 
and CD5 6+ ,  and are a s ubset o f  the l arge granu l a r  
l ymphocytes 1 4 • There i s  increas ing evi dence t h a t  t h e  second 
group o f  l ympho cyt e s , LAK ce l l s ,  are not a separate l ineage 
but repre s ent act ivated NK ce l l s 17 • LAK ce l l s  are produced 
by s t imul a t ing norma l NK ce l l s  with h i gh do se I L - 2  ( > 1 0 0 0  
Uni t s /ml ) . They are cha racteri zed by the ir ab i l i t y  to  l yse 
a variety o f  fresh and cul tured target ce l l s  wi thout ant i gen 
spe c i f i c i t y18 • As a consequence the i r  cytotoxic poten t i a l  
i s  not MH C  r e s t r i cted . Las t l y ,  CTL are a subset o f  T­
l ymphocytes w i th surface CDS+ express ion whi ch ki l l  target 
ce l l s  express i ng speci f i c  anti gen18 • The i r  purpo s e  in 
immune surve i l l ance i s  to recogn i z e  forei gn pept ides der ived 
f rom intrace l lu l a r  ant i gens associated with s e l f  MHC c l a s s  I 
mo lecules and to  l yse the se ce l l s 13 • A ma j or i t y  o f  
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c i rcul a t ing CTL are not ful l y  di f ferenti ated and act ivation 
requ i re s  ant i gen recogni t i on a long with cytokine s t imulat ion 
usu a l l y  provided by CD4 + regul atory lymphocytes1 4 • 
To det ermine the ce l l  typ e  re spons ible for conferr ing 
tumor immuni t y  in our anima l s ,  in vi t ro cytotox i c i t y  a s s ays 
were conducted . Cyt o t ox i c i t y  was measured by the abi l i t y  o f  
spl enocyt e s  to  l yse 5 1Cr  l abeled target ce l l s . I n  o rder to 
di f f erent i ate between the three cytotoxic ce l l  t ypes , 
cytotox i c i t y  was mea sured direct l y  f rom fresh l y  harves ted 
sp l enocyt e s  and a l s o  f rom c e l l s  seconda r i l y  s t imul ated with 
i rradi a t ed aut o l ogous tumor ce l l s  and RTS . NK cel l s  require 
no s e condary s t imu l a t ion and their activity can be detected 
from the freshly harve s t ed immune cel l s . I n  cont ras t ,  CTL 
responses o n l y  o ccur i n  vi vo and to detect CTL a c t i v i t y  i n  
vi tro requi res secondary s t imul a t i on a l ong with regul atory 
l ymphocytes for anti gen present a t i on . The i rradiated 
aut o l o gous tumor cel l s  provide the ant i gen and RTS provides 
the nece s s ary cyt o k i ne s t imul at ion . The t arget ce l l s  
inc luded the autologous tumor ce l l s  ( 9L or  RT2 ) to  whi ch the 
animal had been primed,  C 6  an a l logene i c  g l i oma in o rder to 
det e rmine MHC restri cted cytotox i c i t y  and MatB , a s yngene i c  
unr e l a t e d  adenocarcinoma to de termine tumor speci f i c i t y . 
LAK ce l l  a c t i v i t y  would be mani fest a s  l ys i s  o f  the 
s yngene i c  tumo r ce l l s  as  well as  the al l ogene i c  C6 t a rget 
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c e l l s  and MatE target c e l l s . I n  cont ra s t ,  CTL a c t i v i t y  
woul d  exh ib i t  as  spec i f i c  l y s i s  o f  only t h e  tumo r ce l l s  u s e d  
for immun i z a t i on .  
Figure 8 represents the resul t s  o f  a var i e t y  o f  i n  
vi t ro cyto l yt i c  a s s ays f rom fre shl y harve s t ed spl enocyt e s  t o  
measure NK c e l l  activi t y . I n  addition to the normal g l i oma 
t a r ge t s , Yae- l ,  a target ce l l  known to be sens i t ive to NK 
c e l l  c yto l y s i s  was included . Although the mechani sm for NK 
c e l l  suscep t ib i l i t y  for t h i s  ce l l  l ine i s  unknown , it has 
been used extens ive l y  a s  an indicator of NK cell  act ivi t y  i n  
mur ine C T L  a s s a ys . Due to  the lack o f  a rat NK s en s i t ive 
t a r ge t ,  other researche r s  have s imi l a r l y  used Yae- l in rat 
s tudi e s4 8 • I n  these s tudi e s  Yae- l ce l l  l y s i s  from rat 
e f fector ce l l s  r e f l ected l ymphocyte act iva t i on wi thout 
speci f i c i t y  for NK ce l l s . 
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Cytotoxic i ty measured by 4 hour 51Cr release assays agains t 
g l i oma targe t s  wi thou t secondary s t imu l a t i on . Splenocyte 
der ivat i on is g iven in the t i t le . 
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Yae- l ce l l  l ys i s  was e f fector c e l l  dose dependent 
( Fi gure 8 ) . I n  comparing the di f ferent e f fector c e l l  
popu l a t i ons very l i t t l e  di f ference in Yae - l  sens i t ivity was 
observed . At an e f fector to  target r a t i o  of 1 0 0 : 1 , 
app roxima t e l y  3 0 %  Yae- l c e l l  l ys i s  was measured from naive 
control anima l s  which had no expo sure to tumor c e l l s  ( Figure 
SA) . I nt e r e s t ingly,  s imi l a r  leve l s  o f  cytotox i c i t y  against 
Yae- l was me asured f rom an ima l s  exposed to tumor cel l s  by 
growth at t ime of splenocyte harves t  ( Fi gure 8 8 ) , cured o f  
9 L  tumo r b y  AV- TK and GCV treatment ( Fi gure 8 C )  or  immuni z ed 
wi th 9L  g l i oma c e l l s  ( Fi gure 8 0 ) . These data indicated that 
Yae- l l y s i s  was non-spec i fi c . This non-speci f i c  l ys i s  wa s 
po s s ib l y  r e f l ect ive o f  bac kground non- speci fic l ymphoc yte or  
NK a c t i vi t y . The l a c k  o f  a di f ference be tween Yae- l 
cyt o l ys i s  from naive control anima l s  and anima l s  pr imed i n  
vi vo b y  immuni z a t i on w i th tumor ce l l s  sugge s t e d  that Yae - l  
c e l l  l ys i s  w a s  n o t  rel ated to l ymphocyte activa t ion . 
Further indi cat i on that Yae- l was not an NK sens i t ive 
t arget i n  a rat mode l i s  the lack o f  C 6  or MatB l y s i s . True 
NK ce l l s show MHC unr e s t r i cted ki l l ing o f  s yngene i c  and 
al l ogene i c  c e l l  l ines wi thout anti gen spe c i f i c i t y16 • In our 
a s s ays there was a l ack o f  9L,  RT2 or C6 or MatB ce l l  l ys i s . 
P o s s ible caus e s  are e i ther poor o r  nonex i s tent NK c e l l  
medi ated cytotox i c i t y  f rom r a t  splenocytes or  a l a c k  o f  NK 
8 8  
c e l l  s en s i t iv i t y  o f  the target cel l s . S imi lar resul ts  were 
obt a i ned from anima l s  exposed to RT2 tumo rs ( data not 
s hown ) . 
The data pre s ented in Figure 8 was con s i s tent wi th 
repor t s  by Ho l l aday et a l . 4 8  In the ir mode l ,  immun i z a t ion 
wi th 9L  cel l s  f a i l ed to exhibit cytotoxic activi t y  wi thout 
s e condary i n  vi tro s t imul a t i on with 9L tumor ce l l s . Others 
have s imi l a r l y  shown that l ymph node and spl een der ived 
l ymphocytes are r i ch in tumo r spe c i f i c  CTL precursors 
wi thout measurab l e  CTL activity unl ess  s t imul ated w i th 
anti gen and cytokines 1 4 2 • The mo st frequent l y  employed 
s e condary s t imu l a t i on protoco l uses low do se I L- 2  ( 1 0  
Uni t s /ml ) and i rradi ated auto logous tumor cel l s . Howeve r ,  
p i l o t  s tudi es in our l aboratory have shown augmented CTL 
act ivi t y  a fter seconda ry s t imulat ion with autol ogous tumor 
cel l s  and RTS ( da t a  not shown ) . RTS i s  a cytokine r i ch 
medium derived from Con A st imulated rat spl enocyt e s . 
Hence , our s e condary s t imul at ion protocol was a modi f i c a t i on 
o f  the method o f  Ho l l aday et al . 38 , rep l acing I L- 2  wi th 
medi a  containing 1 0 %  RTS . To account for non- spe c i f i c  RTS 
s t imu l a t i on of e f fector cel l s ,  Figure 9 represents CTL 
a s s ays a fter a 6 day i n  vi t ro s t imul a t i on of e f fectors with 
an unr e l ated cell l ine , the s yngene i c  nasal carcinoma Fat- 7 ,  
and RTS . 
Figu re 9A - E f f ec t or Spl enocyte s  
Der ived From Naive Cont rol Anima l s  
50,-
----------------------------� 
Ill ·r-1 Ill 40. 
� 
"g 30. 
-4-1 
u 
Q) 
� 20.; 
� 
0 
tJ 
o'f 10• 
Ill 
-� 40 
� 
"g 30 
-4-1 
u 
Q) 
� 20 
� 
0 
tJ 
o'f 10 
E f fector to Target Rat io 
F i gure 9 B  - E f f ector Sp l enocyt e s  
Derived From Anima l s  W i t h  A 
Subcutaneous 9 L  Tumor 
0 ...... �---�----��� 
10 . 0  7 . 5 5 . 0 2 . 5  0 . 0 
E f f ec tor to Target Rat io 
--- 9L 
.....- c6 
....._ RT2 
� MatB 
.... 9L 
... C6 
.... RT2 
� MatB 
8 9  
Cytotox i c i ty measured by 4 hour 51Cr release as says aga ins t 
g l i oma targe t s  a f ter a 6 day secondary s t imu lat ion o f  
spl enocytes wi th Fat - 7  and RTS . Spl enocyte derivat ion i s  
g iven in the t i t l e . 
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The s e condary i n  vi tro s t imul a t ion yielded very few 
viable l ymphocyt e s  at the end of the co- incubation period . 
The s e  l ymphocytes showed no s i gn i f i cant toxicity against 
g l i oma targets  a t  an e f fector to t arget ratio o f  1 0 : 1  or 
l e s s . Exposure to tumo r by AV- TK abl a t i on or  by 
immun i z a t ion f a i l ed to  e l i c i t  CTL responses when seconda r i l y  
s t imul a t ed w i th RTS and the non- g l i oma ce l l  l ine Fat - 7  
( Fi gure 9C and 9 D ) . The l a c k  o f  measurable target c e l l  
l ys i s  i ndicated that cytokine s t imul a t i on by RTS w a s  not 
s u f f i c i ent to  di f ferent i a t e  CTL precursors to act ive CTL 
wi thout the pres ence of the ant igen to  which ce l l s  had been 
p r imed i n  vi vo . I n  this  cas e ,  the lack o f  autol ogous tumo r 
s t imul at i on resul ted in poor l ympho cyte pro l i feration wi th 
minima l C TL activi t y .  
I n  Fi gure 1 0 ,  sp lenocytes were i n  vi tro s t imu l a t ed with 
i r radi ated 9L cells and RTS . 
F i gure l OA - E f fector Spl enocyte s  
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Cytotoxic i ty measured by 4 hour 5 1Cr release assays agains t 
g l i oma target s  a f ter a 6 day secondary s t imulat ion o f  
splenocytes wi th 9 L  c e l l s  and RTS . Splenocyte der ivat ion i s  
g iven in the t i t le . 
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I n  Figure l OA, spl enocyte CT1 activity from control 
nai ve anima l s  is dep i cted . Thi s  cont ro l was conducted to  
correct for CT1 activity generated as  a consequence o f  the 
i n  vi tro s t imu l a t ion pro tocol w i th 91 g l i oma c e l l s . Target 
cell l ys i s  i s  l e s s  than 3% aga inst 91,  RT2 and C 6  target 
ce l l s . This minimal response indicated that previous tumor 
expo sure i s  neces s ary for secondary s t imul a t i on to activate 
CT1 precursors to  active CT1 . In vi t ro s t imu l a t ion i s  not 
s u f f i c i ent to gene rate a s i gn i f i cant CT1 popu l a t i on capable 
of  l ys ing aut o l o gous g l i oma targe t s . 
I n  Figure l OB ,  CT1 re sponse from splenocytes gene rated 
f rom anima l s  bearing sma l l  91 tumo rs i s  depicted . A very 
l im i t e d  response ( l e s s  than 1 % )  against all target c e l l s  was 
measured . This dimini shed re sponse was mos t  l i ke l y  a 
cons e quence o f  tumor medi ated immuno suppress i on . I n  our 
l aboratory,  a minima l but measurable response was obtai ned 
from anima l s  wi th surg i c a l l y  removed tumors a fter a 
s u f f i c i ent period o f  t ime ( data not shown ) . The l ack o f  
t h i s  minima l response from anima l s  with progre s s ing tumor 
may be due to  a l o s s  o f  respons iveness to cytokine 
s t imu l at ion . Pe ripheral b l ood l ymphocytes from our tumor 
bearing anima l s  showed dimin i shed pro l i feration in response 
to  the mitogens Con A,  PHA and I 1- 2  ( data not shown ) . 
S imi larly,  much fewer viable l ymphoc yt e s  were recovered 
9 5  
a ft e r  s e condary s t imul a t i on in cont rast to  e f fectors f rom 
immuni z ed anima l s  ( Fi gure l OD ) . I n  addi t i on to  the l o s s  o f  
cytokine mediated pro l i feration,  CT1 precursors f rom tumor 
bearing anima l s  may a l s o  f a i l  to d i f ferent iate into act ive 
CT1 by ant i gen s t imu l a t ion . 
I n  cont rast to  Figure l OA and l OB ,  in Figure l OC 
e f fector c e l l s  from our AV-TK treat ed- 91 ab lated anima l s  
showed s i gni f icant cyto l yt i c  k i l l ing o f  91 and R T 2  g l i oma 
t a rget ce l l s . Interes tingl y,  thi s cytotox i c i t y  was not 
tumor spec i f i c  but gl ioma speci f i c . There was l imited l y s i s  
o f  t h e  s yngene ic breast adenocarcinoma ce l l  l ine MatB . 
Howeve r ,  s i gni f i cant l ys i s  o f  both the s yngene i c  gl i oma ce l l  
l ines 9 1  and RT2 was me asured a t  e f fector t o  target r a t i o s  
o f  5 0 : 1  and 1 0 0 : 1 .  Thi s  g l i oma cross reactivity has been 
repor t ed38 and is postulated to be a resu lt of a common 
g l i oma ant i gen expressed by both ce l l  l ines . Thi s g l i oma 
spec i f i c  CT1 response f a i l ed to l yse the a l logene i c  C 6  
g l i oma t arget ce l l  l ine . Howeve r ,  thi s observa t i on 
sugge s t ed CT1 ce l l s  as  immune e f fector ce l l  popu l a t ion 
i n s t e ad of LAK c e l l s  whi ch would exhibit MHC unr e s t r i cted 
l ys i s  of C6  cells ( data not shown ) . 
I nteres t ingl y ,  the immune response from anima l s  with 
ab l a t e d  91 tumors by AV- TK and GCV ( Fi gure l OC )  was s imi l a r  
to t h a t  f rom animal s  immuni z ed wi th 9 1  tumor ce l l s  and BCG 
9 6  
( Fi gure 1 0D ) . The immune re sponse was s l i gh t l y  greater 
against gl i oma target ce l l s  from immuni zed anima l s ,  howeve r ,  
this d i f f erence was not s t a t i s t i c a l l y  s i gni fi cant . The se 
data sugge s t e d  that AV- TK plus GCV treatment o f  tumors was 
s imi l a r  to tumor ce l l  vacc ination in i t s  abi l i t y  to generate 
a CTL immune r e spons e . 
Figure 1 1  represent s a s imi l ar s tudy conducted with 
anima l s  expo sed to RT2 . 
Ill .... 
Ill 
:>t ..:l 
'0 Q) .j..) u Q) .... .... 
0 
u 
o'f 
Ill .... 
Ill 
:>t ..:l 
'0 Q) .j..) u Q) .... .... 
0 
u 
o'f 
1 0  
9 
8 
7 
6 
5 
4 
3 
2 
F i gure l lA - Ef fector Splenocyt e s  
Der ived From Naive Cont rol Anima l s  
1 00 75 50 25 
E f fector to Target Rat io 
0 
F i gure l l B  - Ef fector Sp lenocyte s  
Derived From Anima l s  With A 
Subcutaneous RT2 Tumor 1 0 0,-------------------------------� 
9 0-
s o. 
7 0. 
6 0· 
s o. 
4 0  • 
3 o. 
2 0. 
1 0· I .:r 
0 • T -
1 0 0  7 5  5 0  2 5  0 
Ef fector to Target Rat io 
.... 9L 
..... C6 
..... RT2 
-+- MatS 
.... 9L 
..... C6 
..... RT2 
-+- MatS 
Cytotoxic i ty measured by 4 hour 5 1Cr release assays aga ins t 
g l i oma targe t s  a f ter a 6 day secondary s t imulat ion o f  
splenocytes with RT2 c e l l s  and RTS . Splenocyte der iva t ion 
is given in the t i t l e . 
9 7  
Ill 
•ri 
Ill 
;; 
'0 Q) .j.) u Q) H H 0 u 
1 0 0  
9 0  
F igure l l C  - E f fector Splenocyte s  
Der ived From Anima l s  Cured o f  RT2 
Tumors by AV-TK and GCV Treatment 
8 ot-IIIIIIIC:===:::===-.�!'11. 
7 0  
6 0  
5 0  
4 0  
3 0  
2 0  
1 0  
0 
1 0 0  7 5  5 0  2 5  
Ef f ec t or to Target Rat io 
0 
F i gure l l D - E f f ec tor Splenocyt e s  
Der ived From Anima l s  Immuni zed 
With RT2 Gl ioma Ce l l s  1 0 0�------------------------------.. 
9 oC:===---.-.... ...._-:iliii 8 0-=t:" 
7 0  
6 0  
5 0  
4 0  
3 0  
7 5  5 0  2 5  
E f f ec tor t o  Target Rat io 
0 
..... 9L 
.... C6 
.... RT2 
-+- MatS 
9L 
C6 
RT2 
MatB 
9 8  
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i s  g iven in the t i t l e . 
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The s e  data we re qui t e  s imi l a r  t o  that generated with 9L 
tumor exposure ( Fi cure 1 0 )  except for the degree of measured 
CTL a c t i vi t y .  There was s i gn i f i cant l y  greater measured 
l ys i s  o f  s yngeneic g l i oma targets from the RT2 p rimed 
anima l s  ( > 8 0 % )  as compared to 9L primed anima l s  ( Fi gure 
1 0D ) . Our e a r l i e r  studies ( Fi gure 2 )  demonstrated that RT 2 
was better at generating a measurable immune response than 
9L ( Fi gure 2 ) . Thi s  s t ronger CTL response may be indi cat ive 
of the greater tumo r re sponse rate when treated w i th AV- TK 
and GCV ( Tabl e  I I I ) . Of  intere s t , the CTL response f rom RT2 
abl ated or immuni z ed anima l s  was MHC restri cted and g l i oma 
speci f i c  but not tumo r speci f i c . The glioma cro s s ­
react i vi t y  from RT2 primed e f fector ce l l s  as  we l l  as from 
the 9L e f fector ce l l s  ( Fi gure 1 0 )  further supported the 
hyp o the s i s  for a common anti gen shared by these c e l l  l ines . 
The common paradi gm i s  for vira l l y  induced tumors to  express 
an ant igen rel ated to the t rans forming virus whi l e  
chemi cal l y  der i ved tumors express a n  ant i gen related to  a 
mut ageni zed pro tein . These ce l l  l ines vary in the i r  
deriva t i on . 9L was ethylni t ro surea de rived14 3  and RT2 was 
avi an- s a rcoma virus induced1 4 4 • The cross reactivi ty 
me asured by our a s s a ys indicated these ce l l s  do not fo l low 
this  paradigm .  These c e l l  l ines a l s o  vary great l y  in 
morpho l o g y  and growth characte r i s t i c s . Hence , the common 
1 0 0  
shared anti gen may be g l i oma spec i f ic . 
The next addre ssed que s t i on was regarding CTL ac t ivity 
f rom anima l s  with ablated tumors which rej ec ted sec ondary 
engra f tment o f  tumor igenic and l e tha l doses of tumor c e l l s . 
We hoped to de termine i f  a second tumor c e l l  exposure wou ld 
s erve t o  augment the CTL re sponse . Measurement o f  CTL from 
anima l s  rej ec t ing a secondary 9 L  tumor cha l l enge i s  g iven in 
Figure 1 2 . 
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Cytotoxic i ty measured by 4 hour 51Cr release assay aga inst 
the syngenei c  g l i oma target 9L and the a l l ogene ic g l i oma C6 
target c e l l s . Naive = Poo led splenocytes from 3 anima l s  
never exposed to 9 L  tumor c e l l s . 9 L - 3  = Poo led spl enocytes 
f rom 3 anima l s  with 65 mrn3 subcutaneous 9 L  tumors ablated by 
AV-TK and GCV treatment which subsequen t ly rej ec ted 
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s econdary tumor engra ftment a fter subcutaneous inoculat ion 
o f  3 X 1 06 9L  ce l l s .  9L- 3 0  = Poo led sp lenocytes f rom 3 
animal s  wi th 6 5  mm3 subcutaneous 9L  tumors ablated by AV-TK 
and GCV treatment which subs equent l y  rej ected s e condary 
tumor engr a f tment a fter subcutaneous i nocu l a t ion o f  3 X 1 07 
9L  c e l l s . For the latter 2 group s ,  splenocytes were 
harves ted 2 weeks a fter the secondary tumor cha l l enge . 
The CTL r e sponse f rom anima l s  cured o f  ini t i a l  9L 
tumors by AV- TK and GCV trea tment with subsequent rej ection 
o f  tumo r i genic and l e thal do ses of 9L ce l l s  was 
approxima t e l y  2 0 %  agains t the 9L g l i oma target ce l l s . 
Greater l y s i s  o f  9L  target cel l s  was seen with anima l s  
s e conda r i l y  expo sed t o  3 X 1 07 tumor c e l l s  in compari son t o  
t h a t  observed from anima l s  rej ecting 3 X 1 06 9L ce l l s . Thi s  
di f f erence i n  9L  t arget cell  l ys i s  was not s t at i s t i c a l l y  
s i gn i fi cant . Of  intere s t ,  measured target ce l l  l y s i s  was 
s imi l a r  to leve l s  me asured f rom anima l s  wi thout se condary 
tumor cha l l enges ( Fi gure 9C ) sugge st ing that secondary tumo r 
ce l l  inocul a t ion did not augment CTL precursor 
di f feren t i a t i on into act ive CTL . 
To further conf i rm our obs e rvat i ons regarding CTL 
med i a ted l y s i s  for both 9L and RT2 cel l s ,  CTL a s says were 
conducted with puri f i ed popu l a t ions of CDS+ and CD4+ c e l l s  
( da t a  n o t  shown ) . Bul k splenocytes from anima l s  wi th 
ab l ated tumo rs by AV-TK and GCV treatment were dep l e ted o f  
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C D 4 +  o r  C D B +  c e l l s  b y  co- incubat i on with antibodi es directed 
against these surface mo l ecules and compl ement . CTL 
a c t i vi t y  was e f fectively blo cked to  approximately 5%  o f  the 
cytotox i c i t y  o f  the bul k  population when depl eted o f  CDB+ 
c e l l s . I n  con t ra s t ,  c ytotox i c i t y  wa s not e f fected o r  
enhanced in tho s e  popu l at i ons con s i s t ing o f  CD4 + depl eted 
c e l l s . I ncub a t i on o f  the s econdary ant ibody and comp l ement 
d i d  not a l t e r  cytotoxi ci t y . To further con f i rm CDB+ 
cytotoxic T l ymphocyt e s  were respons ible for target ce l l  
l ys i s ,  the e f f ector c e l l  showing MHC restri cted cytotoxicity 
was c loned by l imi ting dilution and pheno typed . FACS 
ana l ys i s  i den t i f i ed the e f fector ce l l  as CDBcr+CDBB+ w i th 
abundant crB t - ce l l  receptor ( data not shown ) . This surface 
phenot ype was con s i s t ent wi th CTL cel l s . I n  ra t s ,  NK ce l l s  
whi ch d o  n o t  undergo thymic maturat i on express CDBcr 
homodimers and l ack CDBB expre s s i on . I n  contrast CTL 
exp r e s s  CDBcrBB het e rodimers . A NK c e l l  mar ker was not 
ava i l ab l e  l imit ing direct immunophenotyp ing . 
In vi t ro cytotox i c i t y  unfortuna t e l y  may not be 
indicat ive o f  the in vi vo s i tuation . Many unaccountable 
var i ab l e s  make CTL ass ays suspect . Mea sured cyotox i c i t y  can 
vary depending on the length of secondary incubat ion1 4 5 , the 
r a t i o  o f  e f fector : s t imulator ce l l s  during the incub a t i on14 5 , 
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a s  wel l a s  t emperature and l ength o f  the CTL a s s ay ( data not 
shown ) . Las t l y ,  RTS var i e s  w i th l o t . The amount and ratio 
of  the cytokines conta ined in e ach lot  was not de t e rmined . 
O f  great concern was the weak c yt o l yt i c  re sponse 
measured f rom AV- TK and GCV treated- 91 ablated anima l s  
( Fi gure 1 0C ) . The actual i n  vi vo e f f i cacy o f  ce l l s  
exhibi t i ng approxima t e l y  2 0 %  cyt o l ys i s  i n  vi tro a t  an 
e f fector to  target ratio o f  1 0 0 : 1  was que s t ionab l e . To 
det e rmine the actual in vi vo e f f i cacy of e f fector ce l l s  a 
var i e t y  o f  adopt ive t rans fer experiment s  were conducted . 
I f  tumo r immunity was t rans ferred from tumo r eradicated 
anima l s  without secondar y  s t imul a t i o n ,  actual i n  vi vo 
e f f i cacy could be proven . Resul t s  o f  adoptive t rans fer 
experiments from AV-TK plus GCV treated 91 and RT2 abl ated 
animal s  to  naive anima l s  i s  depi cted . Spl enocyt es were 
given by int raper i toneal inj ect i on to  na ive anima l s  which 
were s ub s e quent l y  chal l enged with the minimum tumor forming 
dos e  ( 3  X 1 0 6 91  or  2 X 1 06 RT2 ) of tumo r cel l s . 
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TABLE VI - RESISTANCE TO TUMOR ENGRAFTMENT AFTER 
ADOPTIVE TRANSFER OF UNSTIMULATED SPLENOCYTES FROM ANIMALS 
WI TH SUBCUTANEOUS GLIOMAS ABLATED WITH AV-TK AND GCV 
TREATMENT 
Donor Cell Number Secondary Animal s  
Lymphocytes Transfered Tumor Rej ecting 
Chal lenge Tumor 
5 X 1 0  9L 0 / 6  
Nal.ve An ima l s  5 X 1 0° 9L  0 / 5  
5 X 1 0° RT2 0 / 6  
An ima l s  W i th 5 X 1 0° 9L 0/ 6 
a 9 L  Tumor 
Anima l s  W i th 5 X 1 0° RT2 0 / 6  
a RT2 Tumor 
An ima l s  with 5 X 1 0  9L 1 / 8  
9 L  Tumors 
Abl a t e d  by 
AV- TK and GCV 5 X 1 0" 9L 2 / 6  
Treatment 
Anima l s  with 5 X 1 0  RT2 6/6 * 
RT2 Tumors 
Ablated by 
AV- TK and GCV 5 X 1 0° RT2 8/9 * 
T r e a tment 
Splenocytes f rom 3 donor anima l s  ( column 1 )  were poo led and 
given by int rape ri toneal inj ection to naive anima l s . The se 
spl enocytes were harve s t ed f rom anima l s  6 weeks a fter 
i ni t i a l  tumo r i noculat ion and 5 we eks from the commencement 
o f  AV- TK tre a tment . Rec ipi ent animal s  were cha l l enged 3 6  
hours l ater w i t h  the minimum tumo r forming dose o f  9L o r  RT2 
cel l s  on the i r  r i ght do rsal surface approx imately 1 em f rom 
the midl ine . Tumor forma t i on de fined as pa lpable tumor was 
a s s e s s ed 2 weeks from the t ime o f  tumor cha l l enge . Re sults  
rep r e s ent the comb ined averages o f  2 exper iments . Re sul t s  in 
bo l d  ( * )  are s t a t i s t i c a l l y  s i gni fi cant ( p < 0 . 0 5 )  by chi ­
s quare ana l ys i s  when these groups a r e  compared to adoptive 
therapy from nal.ve anima l s  or anima l s  bearing 9L or  RT2 
tumo r s . 
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T r ans fer o f  splenocyt es f rom naive o r  tumo r bearing 
animal s  did not confer protect i on to  recipient anima l s  f rom 
tumor cha l l enge s ince no anima l s  rej ected secondary tumo r 
chal l enges a fter adopt ive l ymphocyte transfer ( Table VI ) . 
I n  cont r a s t ,  adopt ive transfer o f  l ymphocytes from animal s  
with ab lated 9 L  tumo rs b y  AV-TK and GCV treatment conferred 
tumor r e s i s t ance ( 1 / 8  and 2 / 6  anima l s ) but was not 
s t a t i s t i c a l l y  s i gn i f i cant . I n  contras t ,  donor l ymphocytes 
f rom AV-TK treated-RT2 tumo r ablated anima l s  prevented tumor 
engra f tment with h i gher e f fi c i ency than from the AV-TK 
treated 9L tumo r  ablated anima l s  ( Tabl e  VI ) . W i th the 
excep t i on of a s i ngle anima l receiving 5 X 1 08 donor 
l ymphocyte s ,  a l l  recipient anima l s  were protected from 
s e condary RT2 tumo r cha l l enge . Th i s  conferred pro tection by 
adop t i ve t rans fer was not dos e  dependent as  the s ingle 
anima l whi ch f a i l ed to rej ect tumor recha l l enge received the 
l arger do se of l ymphocytes . The ab i l i t y  o f  donor 
l ymphocytes from our anima l s  to  confer tumor re s i s t ance 
wi thout secondary s t imul a t i on indi cated that CTL medi ated 
protect i on o f  anima l s  from further tumo r recha l l enge ( Table 
IV)  was f e a s ibl e .  
Our , CTL dat a  and phenotypic ana l ys i s  o f  the c loned 
l ymphocyte ce l l  l ine indi cated that tumor immuni t y  was 
mediated by g l i oma speci f i c  CTL . To further con f i rm the 
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r o l e  o f  CTL i n  mediat ing tumo r regre s s i o n ,  the phenotypes o f  
T I Ls from regress ing tumors were analyzed . AV- TK treated 
tumor immune animal s  were res i s tant to  tumor recha l l enge 
( Table IV) . Cha l l enging these animal s  with 3 X 1 06 ce l l s  
prevent e d  tumo r engra f tment with no palpable tumor 
f o rma t i on . I n  contras t ,  these animal s  f o rmed a smal l  
palpab l e  tumor which regressed ove r 1 4  days when given a 3 X 
1 07 9L  ce l l  cha l l enge . These tumo rs were comp l e t e l y  
el imina ted by day 2 1 . 
Phenot ypic ana l y s i s  was conducted on l ymphocytes 
harve s t ed f rom tumors by enzyme dige s t ion at day 1 0  
fo l l owing a secondary tumo r cha l l enge with 3 X 1 07 9L tumor 
ce l l s .  P i l o t  s tudi es in our laboratory indicated that the 
r a t i o  and pheno t ypes of immune e f fector c e l l s  va r i e s  by 
tumor s i z e w i th l arge tumors cons i s t ing mos t l y  o f  
macrophages whi l e  sma l l e r  tumors cont a i ned CD4 + l ymphocyt e s . 
As a comparat ive cont ro l ,  naive anima l s  were given an 
inoculum o f  3 X 1 07 9L tumor ce l l s  and T I L  were harvested 
only f rom tumo rs approx imating the size  of  tumors from 
recha l l enged anima l s . Actual FACS s t a in ing for CTL i s  given 
in Fi gure 1 3 .  
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F i gure 1 3  - Ana lys i s  O f  TIL Phenotype s I s o lated From Secondary 
9L Tumor s  Given To Anima l s  With Previou s ly Abl ated 9 L  Tumors By 
AV- TK Treatment 
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Tumo r s  f r om 3 anima l s  were poo l ed and TIL harve s t ed and 
s t a i ne d  w i t h  ant i bodi e s  aga i n s t  CDSa and C D S � ( Ph a rm i n i gen ) 
The t op pane l s  r e p r e s e n t  T I L  f rom t umor s  harve s t ed f rom n a i ve 
a n i ma l s . The bot t om pane l s  r epre s en t  T I L  f r om s e c ondary t umor s  
g i ven t o  an ima l s  c u red o f  i n i t i a l  9 L  t umors b y  AV- TK a n d  GCV 
T r e a t me n t . C D S a  pos i t i ve c e l l s  are shown in the upper l e f t  
quadra n t . C D S � pos i t ive c e l l s a r e  dep i c t ed i n  t h e  l ower r i gh t  
quadra n t . C e l l s  exp r e s s i ng b o t h  mar k e r s  s t a i n  i n  t he upper 
r i g h t  quadran t . 
l O S  
NK c e l l s  express CDSa homodime rs14 6 whi l e CTL having 
undergone thymi c maturat i on have sur face CDSaSB 
h e t e rodime r s1 4 6 • Therefore,  s t a ining with the antibodies 
CDSa- PE and CDS B - F I TC ( Pharmingen ) s t ained NK cel l s  
( CDSa+ SB - ) i n  the upper l e f t  quadrant and CTL ( CDSa+ SB+ ) in 
the upper r i ght quadrant . Quant i f i ca t ion o f  ce l l s  in the se 
quadran t s  s howed a s i gni f icant di f ference in the c e l l  type 
and number o f  T I L  between naive tumo r bearing anima l s  and 
our AV-TK t re a t ed- tumor rech a l l enged anima l s . Dur ing norma l 
t umor progres s i on there were few anti gen spec i f i c  CTL . The 
bulk o f  C D S +  ce l l s  were o f  the NK phenotype . I n  contras t ,  
the maj or i t y  o f  C D S +  cel l s  ( 3 0 % ) i n  our recha l l enged anima l s  
w e r e  o f  t h e  C T L  ant i gen speci fic variety . The recha l l enged 
anima l s  having been previ ous l y  expo sed to tumor ce l l s  
generated tumor spe c i f i c  CTL . These CTL c e l l s  were known to 
be pro t e c t i ve against further tumo r engraftment ( Table VI ) . 
3 X 1 07 ce l l  inoculum tumors not harves ted in this  
exper iment cont inued to regress and were eventua l l y  
e l iminated . The greater ratio o f  CTL compo s ing the T I L  from 
these tumo rs i ndi cated CTL we re invo lved in tumor regre s s i on 
and abl a t i on . 
The previous s tudi es aimed to  characterize the immune 
e f fector mechanism re spon s ible for tumor immun i t y . The se 
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s tudi es were important i n  unders tanding the ro l e  o f  host 
immune r e spons e s  in tumor regres s ion . The next que s t ion o f  
interest concerned the r o l e  o f  adenovirus medi ated tumor 
k i l l ing to  f ac i l i tate generat i on o f  tumor immun i t y . 
A var i e t y  o f  protoco l s  have been uti l i zed to  augment 
ant i - tumor immune response generation incl uding tumo r 
vaccinat i on strategies a imed at generating a systemi c immune 
respons e capab l e  o f  medi a t ing tumo r regres s i on o f  d i s t ant 
met a s t a s e s 1 4 7 • For uni focal tumors , researchers have 
a t t empt e d  to upregulate cytotoxic tumor spec i f i c  l ymphocytes 
b y  inj e c t i on of tumors with immune adj uvants such as  BCG69 
and viruses 73 ' 7 4 • Current l y ,  cl inica l treatment o f  
s ubcutaneous tumo rs mos t  o ften invo lves surgical removal o f  
the l e s ion1 • However in many ca s e s ,  there was tumo r r e l apse 
w i th tumors o ccurring a t  fo ci far d i s t ant from the s i te of 
the o r i g inal tumor6 • I n  mo st o f  the se case s ,  tumor 
reoccurrence was att ributed to the l a c k  o f  tumor immuni t y .  
Hence forth,  a n  experiment was conducted t o  determine i f  AV­
TK and GCV were bene f i c i a l over surgical remova l o f  the 
neop l a sm or tumor vacc inat ion strategies in generat i ng an 
ant i - tumor immune respons e .  Given the di f f icu l t y  i n  
gene rating an immune response with 9L tumo r s ,  this  tumor was 
cho sen as the subcutaneous model . 
Varying s i z es  o f  subcut aneous tumo rs were surg i c a l l y  
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exc i s e d . Al l surgica l l y  treated anima l s  rema ined tumor free 
wi thout tumor reoccurrence . Due to  the immuno suppress ive 
nature o f  these g l i omas , the immune s ta tus o f  anima l s  was 
periodi ca l l y  de t e rmined by measurement of periphe ral blood 
l ymphocyte ( PBL ) pro l i ferat ion in response to  mi togen 
s t imul a t ion by 3H - thymidine upt a ke ( data no t shown ) . 
Pro l i f e ra t i on o f  PBL in re sponse to  Con A was me asured at 5 ,  
1 0 ,  1 4 ,  and 2 1  days f rom the t ime o f  tumor resect i on . I n  
compari son to  pro l i feration o f  PBL from naive non- tumo r 
bearing anima l s ,  a 4 0 %  dimi nut i on in pro l i feration was 
measured f rom tumor bearing anima l s  up to day 1 0 . Day 1 4  
and day 2 1  PBL pro l i feration values were equival ent to  
values generated by naive control anima l s  indi cat ing norma l 
immune s t atus . S i nce there was no ho st impairment , on day 
2 4  f rom the t ime of tumor resection ,  anima l s  were given a 
tumo r  innoculum o f  3 X 1 07 ce l l s  on the oppos i t e  s ide from 
the ini t i a l  tumo r . The results are given in Tab l e  VI I .  
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TABLE VI I - COMPARISON OF GENE THERAPY TO ALTERNATIVE 
ME THODS FOR THE TR&ATMENT OF SOLID SUBCUTANEOUS UNI FOCAL 
TUMOR 
Treatment Average Tumor Size Animals Rej ecting 
Tumor 
1 6 8  rrun:J 0 / 3  
Surgical Exc i s ion 2 2 1  rrun' 0 / 3  
2 8 9  rrun' 0 / 3  
3 5 0  rrun' 0 / 1  
Tumor Ce l l  No Adj uvant 0 / 6  
Vaccinat ion 
+ BCG 9/9 * 
Anima l s  with 
Ablated 91 Tumo rs + GCV 1 5 / 1 5  * 
by AV- TK and GCV 
Treatment 
Anima l s  were treated as indicated ( column 1 ) . Surgical 
exc i s i on invo lved di ssect ion o f  the subcutaneous tumor wi th 
1 em free margins wi th s kin closure us ing absorbab le 3 - 0  
suture mat e r i a l . Irrununi zat ion cons i s ted o f  a subcutaneous 
inj ect i on o f  1 0  mi l l i on i rradi ated ( 3 0 0 0  rads ) 91 ce l l s  + 
2 5  ug BCG in 1 0 0  ul o f  PBS . AV- TK and GCV trea tment o f ­
tumo rs was conducted as described in Mate r i a l s  and Methods . 
S e condary tumor cha l l enges were conducted on the oppos i te 
f l ank using 3 X 1 06 91 ce l l s  in 1 0 0  ul o f  PBS . Tumor 
f o rma t i on was a s s e s sed 3 weeks from tumor inocu l a t ion . 
Resu l t s  are a comb ined average o f  3 exper iments . Results  in 
bold ( * )  are s t a t i s t i cal l y  s i gni ficant ( p< 0 . 0 5 )  by chi­
s quare ana l ys i s  when compared to  the poo l ed surgi ca l  
exci s i on group or the tumor vaccina t i on wi thout adj uvant 
treatment group . 
Surgical res ect ion o f  pr imary tumo rs f a i l ed to generate 
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tumor immun i t y . Al l anima l s  with surgical l y  removed primary 
tumors deve l oped a tumo r upon se condary tumo r cha l l enge . 
The s i z e o f  the ini t i a l  tumor had no bearing on this  
outcome . Resea rchers have shown that o f  CTL inf i l t rat ing 
tumo r ,  o n l y  a sma l l  percentage retain the abi l i t y  to  l yse 
tumo r1 5 • The maj o r i t y  o f  CTL were apparent l y  non- func ti onal 
as  a consequence of tumo r  s ecreted factors such as  TGF-B4 3 • 
Of  importance ,  surgical removal o f  the tumo r resul ted in 
measurab l e  in vi tro cytotox i c i t y  aga inst auto logous tumor 
cel l s  ( data not shown ) suggest ing that memo ry CTL precursors 
were generated . However ,  i n  vi vo these CTL had l o s t  the 
func t i onal act ivity nece s s ary to rej ect secondary 
engr a f tment of tumor ce l l s . Researchers have thus attempted 
a l t e rnat ive methods for generat ing protect ive tumor 
immun i t y . 
A recent method for modi fying tumor progre s s ion has 
been through vaccina t i on with i rradi ated or  mutagen i z ed 
tumor ce l l s 14 7 • Thi s  type o f  t reatment was based on 
generat ing an ant i - tumor immune response suffi c i ent to 
result  in regress ion of tumo r at d i s t ant foci . Tumor 
vacc i na t i on s t rategies were success ful in some spec i fi c  
anima l s  mode l s 69 but many concerns over thi s s t ra t e gy s t i l l  
ex i s ted . Interest ingl y, immun i z at i on o f  our anima l s  with 1 
X 1 07 i rradi ated 9L ce l l s  was not protect ive against 
s e condary tumor cha l l enge . Fo r the wea k l y  immuno genic 9L 
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tumo r ,  the presence o f  non-dividing ce l l s  was not s u f f i c i ent 
to gener a t e  an anti tumor immune re sponse ( Table VI I ) . 
Generation o f  tumor immuni t y  by immun i z a t i on requ i r e d  9L 
ce l l  inocu l a t ion with BCG,  an immune adj uvant . An immune 
adj uvant was nece s s a r y  to pr ime host immune e f f ector ce l l s  
t o  t h e  i r radi ated 9 L  cel l s . The mechani sm o f  this  adj uvant 
e f fe c t  in this  tumor mode l is unknown . 
As expected,  anima l s  w i th an average o f  6 5  mm3 tumors 
abro gated w i th AV- TK and GCV treatment were res i s t ant to 
s econdary cha l l enge of tumor ce l l s  on the oppo s i t e  f l ank 
f rom the s i te of the ini t i a l  tumor . The se data are 
s i gni f i cant in that immuni z ation s trategies lacked the 
ab i l i t y  t o  generate an immune response wi thout the help o f  
a n  immune adj uvant such as  BCG . Recombinant adenoviruses 
were shown to  e l i c i t  pro i n f l amma tory cytokines such as I L- 6  
and I L - 8  f rom per iphe ral blood l ymphocyt es 14 8 • Fur ther 
evi dence i n  mi ce indicated that se rum inter feron-y l eve l s  
. d . 1 4 9  r 1 s e  upon a enov1 rus exposure . Ear l i e r in this paper we 
r eported that AV- TK and GCV tumo r ab l ated anima l s  have 
generated l ong term tumor spec i f i c  immunity ( Tab l e  IV and 
V ) . Generat ion o f  this tumor immuni t y  may be r e l a t e d  to an 
antiviral immune response gene rated against the adenovi rus 
wi th the adenovi rus serving as an immune adj uvant . I n  the 
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case o f  AV-TK intratumo ral inj ection,  tumor cell  l ys i s  by 
HSVTK gene trans fer coupled to  pos s ib l e  adenovirus mediated 
infl amma t i o n  may t o gether faci l i tate generation of tumor 
immun i t y . 
T o  d e t e rmine the r o l e  o f  adenovi rus- immune s ys t em 
interaction in al tering 9L  tumor progress ion,  T I L  pheno types 
we re ana l yzed a f t e r  adenovi rus inj ection . At day 1 ,  day 4 
and day 7 f o l l owing intratumoral adenovi rus inj ection,  
tumo rs were exc i s e d ,  en z yma t i cal l y  disas sociated and the TIL  
were immunopheno typed and quanti f i ed . On day 1 ,  a 
de t e c t ab l e  di f ference in the numbe r  or T I L  pheno typ e s  was 
not found within non- treated tumo rs and those tumors t reated 
with AV- TK or with AV-TK plus GCV ( data not shown ) . I n  
cont ra s t ,  a s i gni f i cant di f ference in T I L  phenot ypes was 
seen by day 4 ( Tab l e  X ) . As stated earl i e r ,  p i l o t  s tudi es 
in our l aboratory i ndicated TIL phenot ypes varied grea t l y  
depending o n  tumor s i z e . By day 4 ,  the AV- TK plus GCV 
treated tumors were con s i derab l y  sma l l e r  than the other 
treatment groups . A direct comparison was not p o s s i b l e  
wi thout correct ing f o r  t h e  numbe r o f  tumo r ce l l s . 
Un fortun a t e l y ,  a tumor ce l l  mar ker was not ava i l ab l e  
Ther e fo r e , the goal in t h i s  expe riment was to de t e rmine 
gener a l  t rends associated with adenovi rus admini s t r a t ion . 
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TABLE VI I I  - COMPARI SON OF TUMOR INFILI TRATING LYMPHOCYTE 
PHENOTYPES AFTER INTRATUMORAL INJECTION OF RE COMBINANT 
ADENOVIRUS VECTORS 
% CD4 + % CDS+ CD4 : CDS 
C on t ro l - 9L Tumor 2 9  3 7  1 : 1 . 2 5  
9 L  Tumo r -AV- T K  2 3  4 4  1 : 2 
I n j e c t e d  
9 L  Tumo r -AV- T K  1 1  3 1  1 : 3 
I n j e c t e d  + GCV 
Admi n i s t r a t i on 
An i ma l s  w i t h  app r o x ima t e l y  2 0 0  mm3 t umo r s  were i n j e c t e d  w i t h  
veh i c l e  ( PB S ) o r  AV- TK . One g roup r e c e i ve d  GCV 
a dmi n i s t ra t i on as s t a t e d  in M a t e r i a l s  and Methods . T h e  
f o u r t h  da y a f t e r  t umo r i n j e c t ion , t umo r s  we r e  s u r g i c a l l y  
e xc i s e d ,  s ep a r a t e d  f rom t h e  s k i n  and d i g e s t e d  i n  t r i p l e  
e n z ym e  s o l u t i on f o r  6 hou r s . V i a b l e  l ympho c yt e s  w e r e  
o b t a i ne d  by s ep a r a t i on o n  l ympho l y t e  r a t  ( Accur a t e ) . T I L  
f rom 3 a n i ma l s  w e r e  poo l e d ,  s t a i n e d  and ana l y z e d  b y  FACS . 
D a t a  w a s  c o r r e c t e d  f o r  t h e  t o t a l  numb e r  o f  l ymph o c y t e s  by 
co - s t a i n i n g  w i t h  a pan- l ympho cyt e a n t ibody ( PX - 5 2 , 
P h a rm i n i g e n ) .  S im i l a r  r e su l t s  have b e e n  s e en i n  r e p e a t  
e xp e r iment s .  
T h e  p e r c e n t a g e  o f  pos i t i ve l y  s t a i ned C D 4 +  and C D 8 +  
l ympho c yt e s  w e r e  no rma l i z ed t o  t h e  t o t a l  numb e r  o f  
l ympho c yt e s  b y  co - s t a i n i n g  w i t h a pan- l ympho c y t e  ma r k e r  ( OX -
5 2 , P h a rm i n g e n ) .  The mo s t  s i gn i f i c ant no t i ceab l e  t r end 
r e l a t e s  t o  C D 4 : C D 8  r a t i o . CDS is t h e  predom i n a n t  ma r k e r  on 
c y t o l y t i c  c e l l s  and whi l e  CD4 r ep r e s e n t s  the g r oup o f  
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regul atory l ymphocytes invol ved in antigen recogn i t ion and 
i n i t i a t ion o f  the immune response . The AV-TK admi n i s tered 
group s howed a marked s h i f t  in the CD4 : CD S  ratio towards 
CDS+  c e l l s  ( Tab l e  VI I I ) . Thi s increased propor t i on o f  CDS 
ce l l s  i n  the tumor was pos s i b l y  a r e f l ection of l ymphocyte 
migra t i on i n  r e sponse t o  adenovi rus induced i n f l amma t o ry 
cytokines resul t ing in more o f  these cel l s  being a t t racted 
t o  the tumo r . Thi s  increa s e  in CDS +  l ymphocyt es was not 
howeve r ,  neces s a r i l y  of any s igni fi cance in vi vo . Treatment 
o f  tumors wi th AV- LacZ or AV- TK wi thout concomi t ant GCV 
admi n i s t r a t i on fai l ed to regre s s  or a l ter the progre s s i on o f  
any tumors i n  numerous experiments ( Table I I ) . Augmentation 
of the host immune response was not s u f f i c i ent to  a l t e r  
tumor progre s s i on wi thout s i gni f i cant HSVTK medi ated tumo r 
regres s ion . The react ivity o f  these T I L  agains t auto l ogous 
tumor was not determined . 
More importan t l y ,  the AV- TK plus GCV treatment g roup 
showed a mor e  drama t i c  shi f t  o f  the CD4 : CDS ratio towards 
the C D S +  ce l l  population . The tumors in this trea tment 
group were con s i derabl y  sma l l e r  than the others due to  the 
GCV medi ated toxi c i t y  for HSVTK gene t rans ferred ce l l s . 
Thi s  s h i f t  was perhaps att ributable to  addi t ional anti gen 
being present as a consequence of dying ce l l s  within the 
tumor . 
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I n  conc lus ion,  intratumoral adenovirus inj e c t i on 
a l t ered the phenotype o f  T I Ls such that greater numbers o f  
cytotox i c  ce l l s  were present within the tumo r upon . Thi s 
incre a s e  in cyto l yt i c  ce l l s  ref lected e i ther incre a s ed 
mi grat i on o f  l ymphocyt e s  to  the s i t e  o f  tumor or greater 
p ro l i f e r a t i o n  of norma l l y  ex i s t ing T I L  upon reduct i on of 
tumor burden . I n  ei ther cas e ,  adenovi rus inj ect ion into the 
tumo r resu l t ed in changes of the local tumor environment in 
f avor of generat ing tumo r immunity . 
DI SCUSSION 
In si t u  retrovirus mediated HSVTK gene trans fer has 
proven suc c es s ful in the erad i c at ion o f  experimental brain 
t S . . 1 d 1 13 6 •  1 3 7  d h h f f . . umor ln anlma mo e s an as s own some e l cacy ln 
human c l in i c a l  t r i a l s 103 . These exper iment s  u t i l ize 
intratumoral inj e c t ions o f  retrovirus vector produc ing 
c e l l s . There are numerous l imi t a t i ons to thi s method103 . 
Vec tor produc ing c e l l s  inf e c t  tumor c e l l s  in c lo s e  proximi ty 
to the in j ec t i on s i te with poor e f f i c i ency97 . Add i t i ona l ly , 
there i s  the poten t i a l  f o r  inser t i onal mutagenes i s  as a 
c onsequence o f  retrovirus integration102 . In contras t ,  
adenovi rus vec tors have a number o f  appeal ing f ea tures 
making them ideal vec tors f or cancer gene therapy . These 
vec tors c an acc ommodate genes as large as 6 kb and c an be 
c oncentrated to very high t i ters 110 . O f  c l inical rel evance, 
the haz ard o f  ins ert i onal mutagenes i s  i s  not a f ac tor . 
S a f e ty s tudi es us ing adenovirus vec tors have shown minimal 
probab i l i ty o f  integration1 1 1 . G iven these advantage s , we 
have evaluated the abi l i ty o f  recombinant adenovi rus to 
in f e c t  a var i e ty o f  norma l and tumor c e l l  types across a 
broad host range us ing a recombinant adenovi rus expres s ing 
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the B - g a 1 a c t o s i dase gene . Adenovirus infectivity i s  a 
receptor mediated proce s s  and hence i s  dependent on 
adenovirus binding medi a t ed by the s tructural fiber 
protein1 09 • The adenovirus receptor has yet to be i dent i f i ed 
however i t s  express ion var i e s  by hos t  and cell t yp e . As a 
consequence , infectivi t y  o f  recombinant adenoviru s ,  
s imi l a r l y , varied by h o s t  and ce l l  type . Rat and mice c e l l  
l ines d i d  n o t  infect a s  we l l  as  human c e l l  l ines . Lympho id 
cel l s  were not sus cept ib le to adenovirus infection . In 
cont r a s t ,  t ransduct i on o f  tumo r ce l l s  including 
me s o thel i omas and g l i omas was very e f fi c ient ( Tabl e  I ) . 
Al ong wi th e f f i c i ent transduct ion o f  numerous cul tured human 
and rat tumo r ce l l s ,  adenovirus gene t rans fer resu l t ed i n  
g r e a t e r  t rans gene expres s i on than could b e  achi eved with 
r e t rovi rus t ransduct i on ( Fi gure 2 ) . The leve l of gene 
exp r e s s ion was dependent on adenovi rus dose and t ransduct i on 
e f f i c i ency . These resul t s  sugge sted that adenovirus ve ctors 
could e f f i cient l y  t ransduce tumors and prove s the 
f e a s ib i l i t y  o f  adenovi rus mediated gene therapy . 
As a s u i ci de gene vector,  the use o f  the herpes s impl ex 
thymidine kinase gene has an intrins i c  advanta ge . Not a l l  
c e l l s  in a tumor need to  be geneti cal l y  modi f i ed in order to  
be susceptible to GCV toxi city92 • Tumors transduced wi th 
vectors expre s s ing the HSVTK gene showed con s i derab l e  
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regr e s s ion when only a fraction o f  the tumor mas s  was 
modi f i ed . This phenomenon has been named the bys t ander 
e f fe c t . Due to the lack of a gene trans fer method a l lowing 
for gene t i c  modi f i c a t i on to  all ce l l s  wi thin a tumor focus , 
the bys t ander e f fect al lows cancer gene therapy us ing the 
HSVTK gene to  be feasible . We have es tabl ished subcutaneous 
rat gl i oma mode l s  ( 9L and RT2 ) and evaluated the i r  in vi t ro 
bys t ander e f fect ( Fi gure 3 and 4 ) . Both cell  l ines 
exhib i t e d  s u f f i c i ent bys t ander k i l l ing when as few as 8 %  o f  
the c e l l s  were modi f i ed b y  adenovirus mediated HSVTK gene 
t rans f e r . Fo r a given dose o f  GCV, RT2 showed greater 
suscep t ibi l i t y  to  bystande r k i l l ing than 9L . Approxima t e l y ,  
twi ce t h e  number o f  9L gl i o sarcoma c e l l s  had to b e  
gene t i c a l l y  modi f i ed to exhibit the bys t ander susceptib i l i t y  
exhibited by RT2 . 
Al though the mechani sm unde rl ying the bys t ander e f fect 
has been exp l ored i n  vi tro95 '  96 ,  its role i n  vi vo has yet to 
be det e rmined . Given the di f fe rence in bys tander e f fect 
between the ce l l  l i ne s ,  we evaluated the e f ficacy of i n  si t u  
adenovi rus mediated HSVTK gene t rans fer t o  resul t i n  tumo r 
regres s ion and abl a t i on . Con founding eva l uation o f  our 
resu l t s  was the di f ference in irnrnuno gen i c i t y  of the two 
gl i oma c e l l  l ines . Tumor irnrnunogeni c i t y  reflects the 
ab i l i t y  of tumor c e l l s  to s t imulate helper and cytotox i c  T-
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l ymphocyt e s  upon recogn i t ion o f  TAA b y  these ce l l s . As 
measured by s t andard CTL ass ays , RT2 generated a much 
s t ronger cyto l yt i c  re sponse from secondary s t imul ated spleen 
cel l s  than could be obtained from animal s  s imi l a r l y  
immun i zed w i t h  9L c e l l s  ( Fi gure 5 ) . Given the demonstration 
that host responses against tumors are predominate l y  through 
c e l lu l ar interact i ons 14 , the ro l e  o f  the immune response in 
augment ing tumo r e radi cation in our experiments mus t  be 
t a ken into account . 
To a s s e s s  the importance o f  bys tander e f fect i n  vi vo, 
adenov i rus treatment e f f icacy was a s s e s s ed us ing a 9L tumor 
mode l in a thymic rat s . These nude anima l s  retain NK c e l l  
a c t i v i t y  but cannot produce a norma l T - c e l l  mediated immune 
r espon s e . This de f i c i ency al l ows for direct evaluat ion o f  
the ro l e  o f  bys tander k i l l ing i n  complete tumo r regres s ion . 
In vi t ro ,  a 6 0 %  decrease in ce l l  p ro l i feration a t  5 uM GCV 
was exhib i ted when as few as 8 %  o f  c e l l s  were transduced 
w i th AV- TK ( Fi gure 3 ) . Howeve r ,  this  level of bys tander 
e f fect may not be achieved in vi vo . R .  Touraine96 has 
conducted in vi vo bys t ander s tudi es where animal s  w i th 9L 
tumo rs composed of a variety of mixtures of 1 0 0 %  retrovirus 
t r ansduced cel l s  and non-t ransduced tumo r ce l l s  are treated 
with GCV . I n  these studi e s ,  comp l e t e  tumor regre s s i on was 
repor t ed when as  few as  2 0 %  of 9L c e l l s  are HSVTK mod i f i e d .  
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The se experiments were conducted i n  immunocompetent animal s ,  
hence , evaluation o f  these results i s  d i f f i cult due to 
pos s ib l e  contr ibut ion by the host immune system .  W i th GCV 
expo sure , the transduced ce l l s  are growth arrested and wi l l  
eventual l y  p e r i sh . Thes e  ce l l s  upon interaction with 
anti gen present ing ce l l s  may elicit an immune response whi ch 
may be re spons ible for further tumor regres s ion . I n  our 
exper iments i n  athyrni c anima l s ,  treatment of 9 1  tumors with 
AV- TK and GCV resulted in partial tumo r regress ion but 
f a i l e d  to  comp l e t e l y  abl ate exist ing tumor ( Table I I I ) . 
Others have r eported s imi l ar resul ts using di f ferent tumo r 
mode l s  in nude an ima l s 1 37 • S i gni fi cant tumor regre s s ion was 
e s t abl i shed but complete eradi cation of an uni focal tumor 
did not o ccur . I n  conclusion,  tumo r ab l at ion requ i red 
invo lvement of the ho s t  immune re spons e .  
Given the knowl edge that host immune responses p l a y  a 
r o l e  in tumo r e radi cation,  we eva luated the role o f  tumor 
anti geni c i t y  as  a de terminant o f  AV-TK treatment e f f i cacy . 
The gl ioma tumo r mode l s  ut i l i zed were the we a k l y  immuno geni c 
91 and the mo re immunogen i c  RT2 ( Fi gure 5 ) . Fo l lowing 
trea tment of both tumors , regre s s i on was dependent on HSVTK 
gene trans fer and GCV admin i s t ration . No o ther comb inat i on 
o f  r e combinant adenovi rus coup l ed with GCV dosing resul t ed 
in tumor regre s s ion or  abl a t ion ( Tab le I I ) . The e f f i c i ency 
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o f  AV- TK and GCV treatment t o  medi ate complete tumor 
el imi n a ti on was dependent on tumor ant i geni c i t y . 
Approxima t e l y  5 0 %  o f  91 tumors between 1 0 0 - 1 5 0  mm3 could be 
e l iminated by HSVTK gene trans fer . I n  contras t ,  1 0 0 %  o f  
l arger R T 2  tumors ( approximately 3 0 0- 3 5 0  mm3 ) were ablated 
wi th the s ame dose of AV- TK . In  certain cases , tumors 
cont inued to  regress during a t ime frame whi ch could not be 
exp l a ined by AV- TK gene t rans fer and GCV sus cept ib i l i ty 
( Fi gure 7 ) . The re fore , adenovi rus medi ated trans fer o f  the 
HSVTK gene requ i r e s  further interaction o f  the host immune 
r e sponse in order to be e f fect ive . 
Current l y ,  retrovi rus medi ated HSVTK gene t rans fer i s  
b e i n g  evaluated in c l inical  t r i a l s 103 •  Based on the early 
success of  these t r i a l s ,  future c l inical  experiments 
ut i l i z ing AV- TK have been propo s ed . Be fore HSVTK gene 
t r ans f e r  become s a viab l e  treatment regimen , factors 
gove rning tumo r suscept ib i l ity to gene the rapy need to be 
det e rmined . W i th a l l  new treatment s ,  there mus t  be a 
s i gn i f i cant advantage over current treatment protoco l s . 
Researchers have curren t l y  concent rated on bystander e f fect 
as  the p r imary de terminant to HSVTK e f fect ivene s s . Our 
resu l t s  evaluating e f fi cacy in nude and immunocompetent 
anima l s  indicated that tumor ant igen i c i t y  instead o f  
bys t ander e f fect better r e f lected AV- TK e f fect iveness as  a 
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tre atment opt i on . 
O f  inter e s t ,  AV- TK and GCV tre atment o f  subcutaneous 
tumors was abl e  to protect anima l s  from further tumor 
engra f tment ( Tabl e  IV) . Deve lopment o f  tumor immuni t y  was 
dependent on complete eradi cation of the tumor by AV-TK and 
GCV . This tumor immuni t y  was long- standing with anima l s  
abl e  to  rej e c t  tumor engr a f tment as  far as 6 months from the 
i ni t i a l  exposure to tumo r ( Tab le V) . I n  characteri z ing this 
memo ry immune re sponse we determined that i t  was mediated by 
CD8aCD85 cytotoxic T - l ymphocytes . This data indi cated that 
host ant i - tumo r immune respons es pl ayed an impo rtant role in 
augment ing and maintain ing tumor regress ion associated with 
AV-TK and GCV admin i s t ration . Devel opment o f  tumor immuni t y  
w a s  expected wi th 9 L  and RT2 because the se tumors express 
anti gens to whi ch prote ctive cel l u l ar immune respons es are 
generated 3 5 . The importance o f  tumor ant igen i c i t y  and host 
immuni t y  in tumor ab l a t i on has rami fications for the use o f  
immunos uppre s s ive drugs such a s  s teroids used frequen t l y  
wi th b r a i n  tumo r pat ients . Furthermore , this CTL re sponse 
was s u f f i c i ent to protect anima l s  from further t umo r 
engr a f tment a ft e r  adopt i ve trans fer ( Table VI ) . The 
importance o f  this  data relates to tumor reoccurrence . By 
generat ing tumo r immuni t y  anima l s  were protected from 
reappearance o f  dis tant me t a s t a t i c  tumor . 
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L a s t l y ,  w e  determined the role o f  adenovirus gene 
therapy to  augment generation of an ant i - tumor immune 
re spons e .  Previous l y ,  rese archers have attempted to  modi fy 
tumor progr e s s ion through upregu l a t i on o f  tumo r speci fic CTL 
by a var i e t y  o f  methods 70 ' 7 1 '  72 including direct i nj ection o f  
adj uvants such a s  BCG69 and viruses such as  mumps 73 and 
rab i e s74 • These protoco l s  have had l imited success mos t  
l i ke l y  as a consequence o f  tumor r e l a t ed immune suppres s i on . 
Other researchers have attempted gen e t i c  modi fi c a t i on o f  
tumor ce l l s  by the t rans fer o f  immunogenic cytokines 10 • The 
succe s s  o f  these protoco l s  was dependent on the tumor model . 
Howeve r ,  AV- TK gene t rans fer i s  un ique in that suicide gene 
t rans fer resul t s  in substant ial  tumor regre s s i on reducing 
the tumor burden ( Figure 7 ) . In add i t ion, adenovi rus es 
i nc luding recombinant adenoviruses are known to interact 
wi th the ho s t  immune system150 • Adenoviruses have been shown 
to upregu l a t e  i n f l ammatory cytokines such as IL- 6 and IL- 8 
i n  vi tro14 8 • I n  animal mode l s ,  CTL have been shown to  be a 
det e rminant in l o s s  o f  recomb inant adenovirus express i on15 1 • 
Thi s  interact i on o f  adenovi rus with the ho s t  immune system 
may addi t i ona l l y  potent i ate genera t i on o f  an ant i - tumo r 
immune re spons e .  Ana l ys i s  o f  T I L  from adenovirus treated 
tumor s  showed a marked shi ft towards CDS+ l ymphocytes ( Tab le 
VI I I ) . This s h i f t  was more drama t i c  with AV-TK and GCV 
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treated tumors mos t  l i ke l y  due t o  a decrease in tumor burden 
and increased tumor anti gen presentat ion . Interestingly,  
adenov i rus inj ect i on wi thout GCV a l s o  resul ted in a shi ft of 
T I L  towards CDS+ T - l ymphocytes . However ,  the exact 
s i gn i f i c ance of this s h i f t  i s  unknown . The reactivi ty o f  
these ce l l s  against tumo r was undetermined . The increase in 
CDS+  c e l l s  may truly represent an increase in tumo r spe c i f i c  
CTL o r  m a y  be directed at adenovirus assoc i ated ant igens . 
This v i rus a s s o c i a ted immune response may ampl i fy the ant i ­
tumo r immune response generated incidental t o  tumo r ce l l  
k i l l i n g  b y  HSVTK gene t rans fer . Therefore,  AV- TK and GCV 
t r ea tment may s e rve to upregulate an anti tumo r immune 
r e spon s e  by s e rving as a tumor vaccination strategy . HSVTK 
gene t r ans fer e f fective l y  decreases tumor burden by 
conferr ing GCV toxi c i t y  and the adenovirus bac kbone can 
incre a s e  tumo r immunogen i c i t y  by serving as  an immune 
adj uvant . 
T h i s  adj uvant e f fect i s  a dist inct advantage for the 
use of adenovirus medi ated HSVTK gene trans fer for use in 
the t r e a tment of sma l l  focal neop l a sms . I n  comparing this 
gene therapy regimen to a l t ernat ive treatment moda l i t i es 
such a s  surgery and tumor vaccinat ion,  these other protoco l s  
f a i led to  generate protect ive tumor immuni t y  ( Tab le VI I ) . 
Lack o f  a memory immune response by these tradi t i onal 
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t r e a tment methods tran s l a t e s  t o  greater suscept ibi l i t y  for 
tumor r e l ap se . 
Adenovirus medi ated HSVTK gene t rans fer with 
concomi t ant GCV administrat ion has numerous advantages 
r e l a t ing to  the genera t i on o f  tumor immun i t y .  
SUMMARY 
W i th greater knowledge into immune sys tem ne tworks and 
the i r  role i n  cancer de f ens e , more e f fec t ive therapeut i c  
s trateg ies c an b e  at tempted . G l i omas have an unique 
interac t i on wi th the immune sys tem . The brain has l ong been 
cons i dered an immune-privi leged organ . However ,  lymphoi d  
c e l l s  a r e  known to c r o s s  the bl ood-brain barrier and migrate 
into the g l i oma parenchyma . Furthermore , g l iomas are known 
t o  express ant igens against which c e l lular immune responses 
c an be generated . The lack o f  a normal cel lular immune 
response 1 s  a consequence o f  tumor secre ted 
immunosuppre s s ive f ac tors whi ch are known to induc e  
suppre s s o r  c e l l s  and to negat ively regulate the f unc t ion o f  
i n f i l trat ing NK and cytotoxic T- lymphocytes . 
Thus i n  order to control human g l i a l  c e l l  cancers 
requ i r e s  tumor express ion of ant igen , an abi l i ty to overcome 
tumor i nduced immune - suppres s ion and a means to a c t ivate and 
expand tumor reac t ive lymphocytes . Adenoviral mediated 
herpes s impl ex thymidine kinase gene trans fer may be abl e  to 
per f o rm a l l  of these func t i ons . AV-TK s igni f icant ly reduces 
tumor vo lume by conferring sens i t iv i ty to GCV . The 
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dimin i shed tumor burden results i n  a decrease o f  secreted 
immuno suppress ive factors . I n  addi t ion,  the adenovirus may 
s e rve as an immune adj uvant in the tumo r mi croenvi ronment . 
Adenov i rus t reated tumors cause a ma rked shi ft i n  the 
phenot ypes o f  tumor inf i l t rat ing l ymphocytes towards the 
cyto tox i c  T - l yrnpho cyte populat ion . I n  comparison to  
surgical remova l o f  tumor ,  or  direct adj uvant inj ection,  AV­
TK treatment faci l i tates gene rat ion o f  tumo r immuni t y  which 
is in part re spons ible for tumor eradication . 
Given the success o f  ret rovi ral mediated herpes s impl ex 
thymi dine kinase in modi fying g l i oma progress ion in current 
c l i n i ca l  t r i a l s , the ab i l i t y  of an adenovi rus vector to 
gene rate an anti tumo r immune response should dramat i ca l l y  
imp rove the therapeut ic e f fi cacy o f  suic ide gene therapy . 
CONCLUSIONS 
1 )  AV- TK and GCV admin i s trat i on ef fec t ively ablated 
subcutaneous tumors in immunocompetent animals . 
2 )  The put a t i ve HSVTK assoc iated bys tander e f fec t l S  not 
s u f f i c i ent t o  resu l t  in tumor eradic a t i on wi thout 
augment a t i on by the hos t  immune respons e . 
3 )  Tumor antigen i c i ty i s  direc t ly related to AV- TK and GCV 
treatment e f f i cacy . 
4 )  AV- TK and GCV treatment o f  subcutaneous tumors resul ts 
in l ong s t andi ng protec t ive immuni ty against further tumor 
f o rma t i on . 
5 )  Tumor immuni ty induced by AV-TK and GCV t reatment i s  
medi ated by CD8aCD8B cytotoxic T- lymphocytes . 
6 )  Adenovirus inj ec t i on has immunomodulatory proper t i e s  and 
may s erve a s  an immune adj uvant . 
1 3 0  
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